Unilife (UNIFF) 10-K 14 Sep 15 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2015	Sep. 04, 2015	Dec. 31, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	UNIS
Entity Registrant Name	Unilife Corp
Entity Central Index Key	1,476,170
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		136,123,818
Entity Public Float			$ 339.5

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Current Assets:
Cash and cash equivalents	$ 12,303	$ 8,368
Restricted cash	2,400	2,400
Accounts receivable	1,530	1,860
Inventories	151	142
Prepaid expenses and other current assets	656	1,108
Total current assets	17,040	13,878
Property, plant and equipment, net	66,148	54,588
Goodwill	9,685	11,830
Other assets	1,256	1,472
Total assets	94,129	81,768
Current Liabilities:
Accounts payable	4,042	3,583
Accrued expenses	5,074	3,339
Current portion of long-term debt	775	613
Deferred revenue	4,942	717
Total current liabilities	14,833	8,252
Long-term debt, less current portion	79,660	54,835
Deferred revenue	17,550	12,550
Total liabilities	$ 112,043	$ 75,637
Commitments and Contingencies (Note 8)
Stockholders' (Deficit) Equity:
Preferred stock, $0.01 par value, 50,000,000 shares authorized as of June 30, 2015; none issued or outstanding as of June 30, 2015 and 2014
Common stock, $0.01 par value, 250,000,000 shares authorized as of June 30, 2015; 131,976,153 and 103,617,278 shares issued, and 131,947,483 and 103,588,608 shares outstanding as of June 30, 2015 and 2014, respectively	$ 1,320	$ 1,036
Additional paid-in-capital	364,817	296,169
Accumulated deficit	(384,580)	(293,731)
Accumulated other comprehensive income	669	2,797
Treasury stock, at cost, 28,670 shares as of June 30, 2015 and 2014	(140)	(140)
Total stockholders' (deficit) equity	(17,914)	6,131
Total liabilities and stockholders' (deficit) equity	$ 94,129	$ 81,768

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	131,976,153	103,617,278
Common stock, shares outstanding	131,947,483	103,588,608
Treasury stock, shares	28,670	28,670

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]
Revenue	$ 13,158	$ 14,689	$ 2,743
Cost of product sales			128
Research and development	52,487	34,111	21,749
Selling, general and administrative	36,176	27,894	32,437
Depreciation and amortization	4,923	4,079	9,487
Total operating expenses	93,586	66,084	63,801
Operating loss	(80,428)	(51,395)	(61,058)
Interest expense	6,368	7,332	2,392
Other income	(226)	(228)	(252)
Change in fair value of financial instruments	4,279	(600)
Net loss	(90,849)	(57,899)	(63,198)
Other comprehensive loss (income):
Foreign currency translation	2,128	(340)	978
Comprehensive loss	$ (92,977)	$ (57,559)	$ (64,176)
Net loss per share:
Basic and diluted net loss per share	$ (0.81)	$ (0.59)	$ (0.78)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]
Beginning balance at Jun. 30, 2012	$ 43,745	$ 758	$ 212,326	$ (172,634)	$ 3,435	$ (140)
Beginning balance, shares at Jun. 30, 2012		75,849,439
Net loss	(63,198)			(63,198)
Foreign currency translation	(978)				(978)
Share-based compensation expense	13,287	$ 27	13,260
Share-based compensation expense, shares		2,611,167
Issuance of common stock from public offerings, net of issuance costs	39,682	$ 156	39,526
Issuance of common stock from public offerings, net of issuance costs, shares		15,605,400
Exercise of warrant to purchase common stock	2,834	$ 14	2,820
Exercise of warrant to purchase common stock, shares		1,424,220
Issuance of common stock upon exercise of stock options	226	$ 1	225
Issuance of common stock upon exercise of stock options, shares		112,332
Ending balance at Jun. 30, 2013	35,598	$ 956	268,157	(235,832)	2,457	(140)
Ending balance, shares at Jun. 30, 2013		95,602,558
Net loss	(57,899)			(57,899)
Foreign currency translation	340				340
Share-based compensation expense	8,316	$ 16	8,300
Share-based compensation expense, shares		1,593,096
Issuance of common stock from public offerings, net of issuance costs	16,856	$ 50	16,806
Issuance of common stock from public offerings, net of issuance costs, shares		5,012,153
Issuance of common stock upon exercise of stock options	2,920	$ 14	2,906
Issuance of common stock upon exercise of stock options, shares		1,409,471
Ending balance at Jun. 30, 2014	6,131	$ 1,036	296,169	(293,731)	2,797	(140)
Ending balance, shares at Jun. 30, 2014		103,617,278
Net loss	(90,849)			(90,849)
Foreign currency translation	(2,128)				(2,128)
Share-based compensation expense	11,775	$ 99	11,676
Share-based compensation expense, shares		9,890,075
Issuance of common stock from public offerings, net of issuance costs	57,134	$ 185	56,949
Issuance of common stock from public offerings, net of issuance costs, shares		18,458,800
Issuance of common stock upon exercise of stock options	23		23
Issuance of common stock upon exercise of stock options, shares		10,000
Ending balance at Jun. 30, 2015	$ (17,914)	$ 1,320	$ 364,817	$ (384,580)	$ 669	$ (140)
Ending balance, shares at Jun. 30, 2015		131,976,153

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net loss	$ (90,849)	$ (57,899)	$ (63,198)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,923	4,079	5,435
Loss on disposal of equipment			4,052
Share-based compensation expense	11,775	8,316	13,287
Recognition of deferred revenue	(125)	(3,187)	(2,623)
Non-cash interest expense	1,896	457
Change in fair value of financial instruments	4,279	(600)
Changes in assets and liabilities:
Accounts receivable	330	(266)	388
Inventories	(9)	(71)	141
Prepaid expenses and other current assets	452	(704)	267
Other assets	87	(427)	(227)
Accounts payable	431	1,062	65
Accrued expenses	2,259	139	355
Deferred revenue	9,350	12,500	725
Net cash used in operating activities	(55,201)	(36,601)	(41,333)
Cash flows from investing activities:
Purchases of property, plant and equipment	(16,633)	(12,149)	(2,240)
Net cash used in investing activities	(16,633)	(12,149)	(2,240)
Cash flows from financing activities:
Proceeds from the issuance of long-term debt	20,000	40,000
Principal payments on long-term debt and capital lease agreements	(606)	(7,616)	(5,024)
Proceeds from the issuance of common stock, net of issuance costs	57,134	16,856	42,707
Proceeds from the exercise of options to purchase common stock	23	2,534	226
Payment of royalty liability	(749)
Payments of financing costs	(52)	(487)
Net cash provided by financing activities	75,750	51,287	37,909
Effect of exchange rate changes on cash	19	95	(10)
Net increase (decrease) in cash and cash equivalents	3,935	2,632	(5,674)
Cash and cash equivalents at beginning of year	8,368	5,736	11,410
Cash and cash equivalents at end of year	12,303	8,368	5,736
Supplemental disclosure of cash flow information
Cash paid for interest	6,467	3,222	2,479
Supplemental disclosure of non-cash activities
Purchases of property, plant and equipment in accounts payable and accrued expenses	$ 497	991	744
Purchases of property, plant and equipment pursuant to capital lease agreements		$ 125	$ 74

Description of Business

Description of Business	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Description of Business	1. Description of Business Unilife Corporation and subsidiaries (the “Company”) is a U.S. based designer, manufacturer and supplier of innovative injectable drug delivery systems that can enhance and differentiate the injectable drugs, biologics and vaccines, or collectively injectable therapies, of its pharmaceutical and biotechnology customers. The Company has a broad portfolio of proprietary product platforms, including pre-filled syringes, wearable injectors, insulin delivery systems, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems and other systems for the targeted delivery of injectable therapies. Products within each platform are differentiated from competitors’ products with a series of innovative features designed to optimize the safe, simple and convenient administration of an injectable therapy. The Company sells its products directly to pharmaceutical and biotechnology companies who incorporate them into the drug-device combination product that is supplied pre-filled and ready for administration by end-users such as health-care providers or patients. Products within each of the Company’s platforms can be customized to address specific customer, therapy, patient and/or commercial requirements. The Company’s growing base of customers include Sanofi, MedImmune, AbbVie, Novartis and Hikma. In addition to the filling, assembly and/or packaging of its product with an injectable therapy, the Company’s customers are also responsible for the regulatory approval, sale and marketing of their final drug-device combination product. With certain of our devices that we could sell directly to healthcare providers or end users without having them pre-filled with a drug by a pharmaceutical company, we would be responsible for the regulatory approval, sale and marketing of the final device. In addition to product sales, the Company can generate revenue and cash receipts from customization programs, upfront fees and exclusivity or royalty payments. The Company is a Pennsylvania based and Delaware incorporated business since 2009, and was originally established in Australia in 2002.

Liquidity

Liquidity	12 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Liquidity	2. Liquidity The Company has incurred recurring losses from operations as well as negative cash flows from operating activities in each of the years in the three-year period ended June 30, 2015 and anticipates incurring additional losses and negative cash flows until such time that it can generate sufficient revenue from the sale, customization, or exclusive use and licensing of its proprietary range of injectable drug delivery systems to pharmaceutical and biotechnology customers. These factors raise substantial doubt about the Company’s ability to continue as a going concern. In order for the Company to continue operations beyond the next 12 months and be able to discharge its liabilities and commitments in the normal course of business, the Company has taken or will take the following steps delineated below, not all of which are entirely within the Company’s control, to address its cash requirements. On July 29, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (the “New Sales Agreement”) with Cantor Fitzgerald & Co., pursuant to which the Company may, from time to time, issue and sell shares of common stock, having an aggregate offering price of up to $25.0 million. Through September 14, 2015, the Company has issued 2,870,689 shares for net proceeds of $3.8 million under the New Sales Agreement. On July 29, 2015, the Company entered into an equity purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which the Company may sell, from time to time, to LPC up to $45.0 million in shares of the Company’s common stock through July 2017, subject to certain limitations and conditions set forth in the Purchase Agreement. Through September 14, 2015, the Company issued 3,244,650 shares of common stock to LPC and received net proceeds of approximately $4.8 million after expenses. On September 2, 2015, the Company announced that it has engaged Morgan Stanley & Co. LLC to conduct a review of strategic alternatives to maximize shareholder value in response to third party initiated expressions of interest. Potential strategic alternatives to be explored and evaluated during the review process may include a possible sale of the Company, a strategic partnership with one or more parties or the licensing of some of the Company’s proprietary technologies. The Company cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction and no assurance can be given that the Company will determine to pursue a potential sale, strategic partnership or licensing arrangement. The Company continues to have discussions with current and prospective customers for many active programs in its commercial pipeline and has executed several agreements featuring a combination of revenue streams including exclusivity fees, device customization programs and supply contracts that have begun to generate cash payments to the Company during fiscal year 2015. The Company expects to continue to execute agreements and generate additional cash payments during fiscal year 2016. Given the substantial size, complexity and long-term duration of many of these prospective agreements, some can take a significant time to negotiate and finalize. The Company’s near-term capital needs depend on many factors, including its ability to manage its costs, the amount and timing of revenue received from customer contracts, and its ability to successfully utilize the above equity facilities. The Company continues to evaluate other financing alternatives to provide additional operating funds on terms that are consistent with the Company’s business plans. In addition the Company has conducted a review of its operations and implemented a plan to reduce operating expenses and delay capital expenditures to align with current business conditions. As part of the evaluation, on September 9, 2015, the Company’s Board of Directors approved a reduction of approximately 17% of its workforce. The workforce reduction is expected to reduce operating costs by approximately $4.3 million. In connection with this initiative, the Company expects to incur a charge of approximately $0.4 million to operating expenses in the three month period ending September 30, 2015. The Company plans to closely monitor expenses and attempt to further reduce, if necessary, the amount of cash used in operating activities and capital spending by scaling back or delaying capital expenditures, delaying investment in further research and development, or further workforce reductions. The Company estimates that its cash and cash equivalents as of June 30, 2015, along with its restricted cash, together with the additional proceeds raised and that may be raised from the Purchase Agreement and New Sales Agreement, and combined with anticipated cash to be generated from existing and prospective customer agreements are expected to provide the Company with sufficient liquidity for 12 months from the date the consolidated financial statements are issued. However, there can be no assurance that such cash from customer agreements or proceeds from the Purchase Agreement and New Sales Agreement will be available when needed, as such sources of liquidity are not entirely within the Company’s control. If the Company is unable to obtain adequate financing or engage in a strategic transaction on acceptable terms and when needed, it will be required to implement further cost reduction strategies. In addition, a breach of any of the covenants related to the Company’s debt instruments could result in a default under the applicable agreements which could result in a higher rate of interest to be paid or the lenders could elect to declare all amounts outstanding under the applicable agreements to be immediately due and payable. If the lenders were to make such a demand for repayment, the Company would be unable to pay the obligations as it does not have existing facilities or sufficient cash on hand to satisfy these obligations and would need to seek alternative financing. These factors, and the factors described above, continue to raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All significant intercompany accounts and transactions have been eliminated in consolidation. On January 27, 2010, Unilife became the parent company of UMSL upon completion of the redomiciliation under Australian law and UMSL’s stockholders and option holders exchanged their interests in UMSL for equivalent interests in Unilife. References to the “Company” include Unilife Corporation and its consolidated subsidiaries, including UMSL, unless the context otherwise requires. References to “Unilife” are references solely to Unilife Corporation. References to A$ mean the lawful currency of the Commonwealth of Australia. References to € or euros are to the lawful currency of the European Union. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition, royalty liability valuation and share-based compensation expense. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist primarily of cash on hand, deposits at banks and other short-term highly liquid investments with original maturities of three months or less. Cash equivalents are stated at cost, which approximates fair value. Accounts Receivable Accounts receivable are stated at amounts due from customers, which also represents the net realizable amount. The Company evaluates the collectability of its accounts receivable on a periodic basis and has historically not recorded an allowance for doubtful accounts. In instances in which management becomes aware of circumstances that may impair a particular customer’s ability to meet its obligation, the related receivable would be written off. Inventories Inventories consist primarily of raw materials. Inventories are stated at the lower of cost or market, with cost determined using the first in, first out method. The Company routinely reviews its inventory for obsolete, slow moving or otherwise impaired inventory and records estimated impairments in the periods in which they occur. Property, Plant and Equipment Property, plant and equipment, including significant improvements, are recorded at cost, net of accumulated depreciation and amortization. Repairs and maintenance are expensed as incurred. Depreciation and amortization expense is recorded on a straight-line method over the estimated useful life of the asset as listed below: Asset Category Useful Lives Building 40 years Machinery and equipment 2 to 15 years Computer software 3 to 7 years Furniture and fixtures 3 to 7 years Leasehold improvements Shorter of leasehold improvement life or remaining term of lease Interest cost incurred in connection with the development and construction of significant new machinery and equipment, as well as facility related costs have been capitalized as one of the elements of cost and are being amortized over the asset’s respective useful life. Interest capitalized during the year ended June 30, 2015 was $2.2 million. There was no capitalized interest during the years ended June 30, 2014 or 2013. The Company evaluates the recoverability of the recorded value of long-lived assets periodically to determine if facts and circumstances exist that would indicate that the assets might be impaired or that the useful lives should be modified. As part of this valuation, the Company develops projections of undiscounted future cash flows of the asset or asset group. The projections of undiscounted cash flows include a combination of revenue from customization and development activities, capital expenses that may be necessary to support projected product sales and commercial product sales. As customization and development activities are completed, commercial product sales are expected to scale-up. Expectations of future commercial product sales included in the projections used for the impairment analysis are based on customer-specific information as well as market estimates relating to the anticipated drugs and therapies being targeted for use with the Company’s products. These projections also include assumptions of future sales growth and profitability based on contracts entered into with customers as well as future contracts to be entered into based on the current discussions and negotiations with existing and prospective customers. Sales projections are based on assumptions including a transition in the market toward patient self-administration of injectable therapies as well as transitions in the market toward biological-based drugs in the pharmaceutical industry development pipeline. The Company’s future sales could also be impacted by factors such as its ability to obtain new and retain existing customers, the timing and extent of the customers’ drug development activities as well as the regulatory approval process, drug efficacy and industry acceptance of injectable therapies. If the Company’s future sales or its projections of future sales are impacted by any one or more of the preceding factors, it will reassess the recorded value of the long-lived assets. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value. Goodwill and Intangible Assets Goodwill is the excess of purchase price over the fair value of net assets acquired in business acquisitions. Goodwill is subject to, at a minimum, an annual impairment assessment of its carrying value. Additional impairment assessments would be performed if events and circumstances warranted such additional assessments during the year. Goodwill impairment is deemed to exist if the net book value of the Company’s reporting unit exceeds its estimated fair value. Estimated fair value of the Company’s reporting unit is determined utilizing the value implied by the Company’s year-end quoted stock price. There were no impairments recorded on goodwill during the years ended June 30, 2015, 2014 or 2013. The Company has one reporting unit. The reporting unit includes its product lines, the base technology for which was obtained as part of our November 2002 acquisition of Unitract Syringe Pty Limited and the manufacturing capability which was obtained in our January 2007 acquisition of Integrated BioSciences, Inc. In estimating the reporting unit’s fair value for purposes of the fiscal year 2015 impairment assessment, management compared the carrying value of the reporting unit to the Company’s market capitalization as of June 30, 2015, which is its annual impairment testing date. The market capitalization of approximately $283.7 million, based on the quoted stock price on NASDAQ was in excess of the Company’s stockholders’ deficit of $17.9 million. Management also considered that market capitalization through early September 2015 continued to be in excess of the carrying value. Definite-lived intangible assets include patents which are amortized on a straight-line method over their estimated useful lives of 15 years and are included in other assets. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When factors indicate a possible impairment, if the sum of the estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset is less than the carrying amount of the asset, an impairment may be recognized. Measurement of an impairment loss is based on the excess of the carrying value of the asset over its fair value. There were no impairments recorded on intangible assets during the years ended June 30, 2015, 2014 or 2013. Deferred Financing Costs Deferred financing costs are included in other assets on the consolidated balance sheets and consist of costs incurred in connection with debt financings. These costs are amortized and included in interest expense over the term of the related debt using the effective interest rate method. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are recorded to the extent the Company believes they will more likely than not be realized. In making such determinations, the Company considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company’s policy is to include interest and penalties related to uncertain tax positions within the provision (benefit) for income taxes within the Company’s consolidated statements of operations and comprehensive loss. Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, the Company measures fair value based on a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. The fair value hierarchy is broken down into three levels based on the source of inputs. The carrying value of financial instruments such as accounts receivable, accounts payable and accrued expenses are reasonable estimates of their fair value because of the short maturity of these items. The Company believes that the current carrying amount of its long-term debt approximates fair value because the interest rates on these instruments are similar to those rates that the Company would currently be able to receive for similar instruments of comparable maturity. The Company has elected to measure its royalty liability at fair value in accordance with ASC 825, Financial Instruments. The fair value of the royalty liability is based on significant inputs not observable in the market, which require it to be reported as a Level 3 liability within the fair value hierarchy. The valuation uses a methodology and assumptions that the Company believes would be made by a market participant. In particular, the valuation analysis uses a discounted cash flow methodology under the income approach based on the present value sum of payments to be made in the future. The fair value of the royalty liability is estimated by applying a risk adjusted discount rate to the adjusted royalty revenue stream. These fair value estimates are most sensitive to changes in the payment stream. Share-Based Compensation The Company grants equity awards to its employees, directors, consultants and service providers. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants and service providers are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility. Foreign Currency Translation The Australian dollar is the functional currency for the Company’s Australian operations. Assets and liabilities denominated in foreign currencies are translated into U.S. dollars at the rate of exchange existing at the end of the period. Revenues and expenses are translated at the average exchange rates during the applicable period. Adjustments resulting from these translations are recorded in accumulated other comprehensive income within the Company’s consolidated balance sheets and will be included in income upon sale or liquidation of the foreign investment. Gains and losses from foreign currency transactions, denominated in a currency other than the functional currency, are recorded in other income within the Company’s consolidated statements of operations and comprehensive loss and aggregated less than $0.1 million for each of the years ended June 30, 2015, 2014 and 2013. Comprehensive Loss Comprehensive loss includes net loss and other comprehensive loss (income). The Company’s other comprehensive loss (income) consists only of foreign currency translation adjustments. Revenue Recognition The Company recognizes revenue from industrialization and development fees, licensing fees and product sales. The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer. The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. Revenue from industrialization and development fees is recognized as services are rendered or upon achievement of the “at risk” substantive milestone events, which represent the culmination of the earnings process related to such events. Substantive milestones can include specific deliverables such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. The terms of these contracts provide for customer payments to be made as services are rendered or substantive milestones are achieved. The Company considers whether a milestone is substantive at the inception of the agreement. The consideration earned from the achievement of a milestone must meet all of the following criteria to be considered substantive: • It is commensurate with either of the Company’s performance to achieve the milestone, or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone; • It relates solely to past performance; and • It is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Payment terms are considered to be standard commercial terms. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the substantive milestone. Fees for completed, substantive milestones, which are dependent upon customer acceptance for non-refundable payment or, if paid, are refundable pending customer acceptance are recognized upon customer acceptance or the termination of refund rights. Advertising Costs Advertising costs are expensed in the period incurred. The Company incurred total advertising costs of $0.2 million for each of the years ended June 30, 2015, 2014 and 2013. Research and Development Costs Research and development expenses consist primarily of payroll and related personnel expenses (including share-based compensation expense), fees paid to external service providers, costs of materials, components and supplies, costs for facilities, tooling and equipment and costs related to developing prototype products and samples used for various evaluation, testing and related activities for existing and potential customers. Research and development expenses are included in operating expenses when incurred. Research and development expenses include costs related to the ongoing development and expansion of the Company’s broad portfolio of injectable drug delivery systems as well as costs incurred in relation to customization, industrialization and development agreements with its customers. These costs are not segregated from the overall research and development costs as they are not readily distinguishable from the rest of the Company’s ongoing research and development expenses. Interest Expense The Company recognizes interest expense in the consolidated statements of operations and comprehensive loss for all debt instruments using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating the interest expense over the relevant period. The effective interest rate is the rate that exactly discounts the estimated future cash payments through the expected life of the financial instrument to the net carrying amount of the financial liability. The application of the method has the effect of recognizing expense payable on the instrument evenly in proportion to the amount outstanding over the period to maturity or repayment. In calculating the effective interest rate, the Company estimates cash flows considering all contractual terms of the financial instrument, including fees for early redemption and all other premiums and discounts. Net Loss Per Share Basic net loss per share is computed as net loss divided by the weighted average number of shares outstanding during the period. Diluted net earnings per share reflect the potential dilution that could occur from common stock issued through common stock equivalents. The dilutive effect of potential common stock, consisting of non-participating restricted stock and outstanding options to purchase common stock, is calculated using the treasury stock method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid, are considered participating securities and are included in the computation of net loss per share according to the two class method if the impact is dilutive. Shares of the Company’s unvested restricted stock are considered participating securities. However, in the event of a net loss, participating securities are excluded from the calculation of both basic and diluted net loss per share. Business Segments The Company operates in one reportable segment, which includes the design, development and manufacture of injectable drug delivery systems. Revenues by geographic location based on location of customer are as follows: Years Ended June 30, 2015 2014 2013 (In thousands) Domestic $ 9,834 $ 5,702 $ 120 International 3,324 8,987 2,623 $ 13,158 $ 14,689 $ 2,743 Reclassifications Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. Recently Issued Accounting Pronouncements In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU 2013-11, “Income Taxes — Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ” In May 2014, FASB issued ASU 2014-09 “Revenue from Contracts with Customers”. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers” which deferred the effective date of ASU 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Early application is permitted only as of annual periods beginning after December 15, 2016, including interim reporting periods within that reporting period. With the deferral, the new standard is effective for the Company, on July 1, 2018, with early adoption permitted one year prior. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has not selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In June 2014, FASB issued ASU 2014-12 “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” which is part of ASC 718: Compensation-Stock Compensation. The guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and not be reflected in the estimate of the grant-date fair value of the award. The guidance is effective for annual periods beginning after December 15, 2015. The guidance can be applied prospectively for all awards granted or modified after the effective date or retrospectively to all awards with performance targets outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not expect a material impact on its financial condition, results of operations or cash flows from the adoption of this guidance. In August 2014, FASB issued ASU 2014-15 “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The guidance requires an entity to perform a going concern assessment by evaluating its ability to meet its obligations for a look-forward period of one year from the financial statement issuance date. Disclosures are required if it is probable an entity will be unable to meet its obligations within the look-forward period. Incremental substantial doubt disclosure is required if the probability is not mitigated by management’s plans. The guidance is effective for all entities for the first annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact this guidance will have on its financial disclosures; however, as the guidance only impacts disclosure, the adoption of this guidance is not expected to have any impact on the Company’s financial condition, results of operations and cash flows. In April 2015, FASB issued ASU 2015-03 “Simplifying the Presentation for Debt Issuance Costs”. The guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its financial statement presentation and any disclosures.

Equity Transactions and Share-B

Equity Transactions and Share-Based Compensation	12 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Transactions and Share-Based Compensation	4. Equity Transactions and Share-Based Compensation During the year ended June 30, 2013, the Company issued 6,154,000 shares of common stock and raised $18.8 million, net of issuance costs, through an underwritten registered public offering. During the year ended June 30, 2013, the Company entered into the old Sales Agreement, pursuant to which the Company, from time to time, issued and sold shares of common stock having an aggregate offering price of up to $45.0 million. During the years ended June 30, 2014 and 2013, the Company issued 5,012,153 shares and 4,990,434 shares of common stock and raised net proceeds of $16.9 and $14.3 million, respectively, under the old Sales Agreement. During the year ended June 30, 2015, the Company issued 5,808,800 shares of common stock and raised net proceeds of $12.4 million under the old Sales Agreement. During the year ended June 30, 2013, the Company issued 4,460,966 shares of common stock for net proceeds of $9.6 million, net of issuance costs, pursuant to a securities purchase agreement. In connection with the securities purchase agreement, the Company issued two warrants to purchase an aggregate of 1,586,988 shares of common stock. The warrants are exercisable at $3.00 per share and will expire five years from the date of grant. The warrants contain exchange features whereby the warrant holders can exchange the warrants for cash or common stock equal to the value of the warrants at the time of exchange, which value is based upon a contractual formula. Based on the terms of the agreements, the Company has determined that the warrants should be classified as a liability. As of March 31, 2013, the Company recorded a liability of $3.0 million related to the negotiated value of the warrants. In April 2013, the exchange feature was exercised for one of the warrants and a total of 1,424,220 shares of common stock were issued in settlement of a warrant to purchase 1,486,988 shares of common stock and the related warrant liability of $2.8 million was reclassified to equity. As of June 30, 2013, one warrant to purchase 100,000 shares of common stock remained outstanding. During the year ended June 30, 2014, the warrant was exercised in exchange for 19,471 shares of common stock and the related warrant liability of $0.4 million was reclassified to equity. During the year ended June 30, 2013, the Company granted certain directors 75,000 shares of common stock that were vested upon issuance, of which 45,000 shares may not be sold or transferred until such time as the director leaves the board of directors for any reason, including a change in control. The weighted average grant date fair value of the shares was $3.17 per share. During the year ended June 30, 2014, the Company granted certain directors 227,500 shares of common stock which may not be sold or transferred until such time as the director leaves the board of directors for any reason, including a change in control, or other permitted circumstances. The weighted average grant date fair value of the shares was $3.95 per share. During the year ended June 30, 2015, the Company granted certain directors 175,000 shares of common stock which may not be sold or transferred until such time as the director leaves the board of directors for any reason, including a change in control, or other permitted circumstances. The weighted average grant date fair value of the shares was $2.83 per share. During the year ended June 30, 2015, the Company issued 12,650,000 shares of common stock and raised $44.7 million, net of issuance costs, through an underwritten registered public offering. The Company intends to use the proceeds from the public offering for investments in its plant, equipment, systems and personnel to further develop its manufacturing and operational capabilities to satisfy current and future customer orders and for working capital and other general corporate purposes. The Company recognized share-based compensation expense related to equity awards to employees, directors, consultants and service providers of $11.8 million, $8.3 million and $13.3 million during the years ended June 30, 2015, 2014 and 2013, respectively. As of June 30, 2015, the total compensation cost related to all non-vested awards not yet recognized was $26.8 million. This amount is expected to be recognized over a remaining weighted average period of 2.10 years. Stock Options and Warrants The Company has granted stock options to certain employees and directors under the Employee Share Option Plan (the “Plan”). The Plan is designed to assist in the motivation and retention of employees and directors and to recognize the importance of employees and directors to the long-term performance and success of the Company. The Company has also granted stock options to certain service providers outside of the Plan. The majority of the options to purchase common stock vest on the anniversary of the date of grant, which ranges from one to three years. Additionally, certain stock options vest upon the closing price of the Company’s common stock reaching certain minimum levels, as defined in the agreements. Share-based compensation expense related to options granted to employees and directors is recognized on a straight-line method over the related vesting term. Share-based compensation expense related to options granted to service providers is recognized ratably over each vesting tranche of the options. During the year ended June 30, 2010, the Company adopted the 2009 Stock Incentive Plan (the “Stock Incentive Plan”). The Stock Incentive Plan initially provided for a maximum of 6,000,000 shares of common stock to be reserved for the issuance of stock options and other stock-based awards. Commencing on January 1, 2012, and on each January 1 st During the year ended June 30, 2015, the Stock Incentive Plan was amended and restated (the “Amended and Restated 2009 Stock Incentive Plan” or “Amended Stock Plan”) to change how the number of shares of common stock that may be issued under the Amended Stock Plan is calculated, to increase the number of shares of common stock available for issuance under the Amended Stock Plan by 10.0 million and to reapprove the Amended Stock Plan for purposes of refreshing the stockholder approval requirement. The following is a summary of activity related to stock options held by employees and directors during the year ended June 30, 2015: Number of Weighted Weighted Aggregate (In thousands) Outstanding as of July 1, 2014 3,922,411 $ 4.67 Cancelled (170,257 ) 5.43 Expired (1,234,000 ) 6.38 Exercised (10,000 ) 2.33 Outstanding as of June 30, 2015 2,508,154 $ 3.78 6.4 $ — Exercisable as of June 30, 2015 1,908,154 $ 3.83 6.2 $ — The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the year ended June 30, 2015: Number of Weighted Weighted Aggregate (In thousands) Outstanding as of July 1, 2014 2,050,000 $ 4.52 Expired (1,000,000 ) 4.86 Outstanding as of June 30, 2015 1,050,000 $ 4.20 1.3 $ 23 Exercisable as of June 30, 2015 1,050,000 $ 4.20 1.3 $ 23 The aggregate intrinsic value is defined as the difference between the market value of the Company’s common stock as of the end of the period and the exercise price of the in-the-money stock options. The total intrinsic value of stock options exercised during the years ended June 30, 2015, 2014 and 2013 was $0.1 million, $1.8 million and $0.1 million, respectively. The Company currently uses authorized and unissued shares to satisfy stock option exercises. The weighted average fair value of stock options granted during the years ended June 30, 2014 and 2013 was $1.67 and $1.69 per share, respectively. There were no stock options granted during the year ended June 30, 2015. The following is a summary of outstanding and exercisable stock options held by employees and directors as of June 30, 2015: Outstanding Options Exercisable Options Range of Exercise Prices Outstanding Weighted Weighted Exercisable Weighted Weighted $0.00 — $5.00 2,190,000 $ 3.50 6.8 1,590,000 $ 3.46 6.6 $5.01 — $7.00 318,154 5.69 4.2 318,154 5.69 4.2 2,508,154 $ 3.78 6.4 1,908,154 $ 3.83 6.2 The following is a summary of outstanding and exercisable stock options held by persons other than employees and directors as of June 30, 2015: Outstanding Options Exercisable Options Range of Exercise Prices Outstanding Weighted Weighted Exercisable Weighted Weighted $0.00 — $2.00 150,000 $ 2.00 0.8 150,000 $ 2.00 0.8 $2.01 — $6.00 900,000 4.57 1.4 900,000 4.57 1.4 1,050,000 $ 4.20 1.3 1,050,000 $ 4.20 1.3 The Company used the following weighted average assumptions in calculating the fair value of options and warrants granted during the year ended June 30, 2014 and 2013: 2014 2013 Number of stock options granted 500,000 810,000 Expected dividend yield 0 % 0 % Risk-free interest rate 1.52 % 1.03 % Expected volatility 55 % 55 % Expected life (in years) 5.5 5.44 The assumptions noted above for the year ended June 30, 2013 do not include amounts related to the warrants to purchase 1,586,988 shares of common stock issued in connection with the Securities Purchase Agreement. The fair value of each stock option was estimated at the grant date using the Black-Scholes option pricing model. The Company has not historically paid dividends to its stockholders and, as a result, assumed a dividend yield of 0%. The risk free interest rate is based upon the rates of U.S. Treasury bonds with a term equal to the expected term of the option. The expected volatility used to value options granted after January 27, 2010 is based upon a blended rate of the historical share price of the Company’s stock on the Australian Securities Exchange and the volatility of peer companies traded on U.S. exchanges operating in the same industry as the Company. The expected term of the options to purchase common stock issued to employees and directors is based upon the simplified method, which is the mid-point between the vesting date of the option and its contractual term unless a reasonable alternate term is estimated by management. The expected term of the options to purchase common stock issued to consultants and service providers is based on the contractual term of the awards. Restricted Stock The Company has granted shares of restricted stock to certain employees, directors and consultants under the Amended Stock Incentive Plan. During the period prior to vesting, the holder of the non-vested restricted stock will have the right to vote and the right to receive all dividends and other distributions declared. All non-vested shares of restricted stock are reflected as outstanding; however, they have been excluded from the calculation of basic earnings per share. For employees, the fair value of restricted stock is measured on the date of grant using the price of the Company’s common stock on that date. Share-based compensation expense for restricted stock issued to employees is recognized on a straight-line basis over the requisite service period, which is generally the longest vesting period. For restricted stock granted to consultants, the fair value of the awards will be re-valued on a quarterly basis and marked to market until vested. Share-based compensation expense for restricted stock issued to consultants is recognized ratably over each vesting tranche. During the year ended June 30, 2015, the shareholders approved the issuance of 4,000,000 shares of restricted stock to the Company’s Chairman and Chief Executive Officer. The restricted stock was granted on November 14, 2014 and is subject to performance-based vesting and also contains service-based clawback provisions. The performance-based vesting will become satisfied based upon the trading price of the Company’s common stock reaching certain minimum levels on NASDAQ for a minimum of 20 out of 30 consecutive trading days, which range from $6.00 to $12.00 per share. The restricted stock was valued at $1.885 per share on the grant date using a Monte Carlo simulation model which is being expensed ratably over the projected vesting period, which is approximately 2.6 years. The restricted stock would be forfeited to the extent not vested on the fifth anniversary of the grant date. In addition, if prior to the fourth anniversary of the grant date he resigns from employment or is terminated for cause, a specified percentage of the previously vested shares would be required to be returned, which ranges from 100% prior to the first anniversary of the grant date to 25%, on or after the third anniversary of the grant date. The following is a summary of activity related to restricted stock awards during the year ended June 30, 2015: Number of Weighted Average Unvested as of July 1, 2014 2,436,061 $ 3.42 Granted 9,507,434 2.83 Vested (947,344 ) 3.54 Cancelled (264,375 ) 3.42 Unvested as of June 30, 2015 10,731,776 $ 2.89 The total fair value of shares vested during the years ended June 30, 2015, 2014 and 2013 was $3.4 million, $6.0 million and $18.2 million, respectively.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	5. Property, Plant and Equipment Property, plant and equipment consist of the following: June 30, 2015 2014 (In thousands) Building $ 32,359 $ 32,188 Machinery and equipment 27,530 21,224 Computer software 2,910 2,675 Furniture and fixtures 1,345 610 Construction in progress 17,601 9,119 Land 2,036 2,036 Leasehold improvements 270 166 84,051 68,018 Less: accumulated depreciation and amortization (17,903 ) (13,430 ) Property, plant and equipment, net $ 66,148 $ 54,588 Construction in progress as of June 30, 2015 and 2014 consisted of amounts incurred in connection with machinery and equipment and facility related costs, including capitalized interest.

Goodwill

Goodwill	12 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	6. Goodwill The changes in the carrying amount of goodwill during the years ended June 30, 2014 and 2015 are as follows: (In thousands) Balance as of July 1, 2013 $ 11,498 Foreign currency translation 332 Balance as of June 30, 2014 11,830 Foreign currency translation (2,145 ) Balance as of June 30, 2015 $ 9,685

Accrued Expenses

Accrued Expenses	12 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accrued Expenses	7. Accrued Expenses Accrued expenses consist of the following: June 30, 2015 2014 (In thousands) Accrued payroll and other employee related expenses $ 2,781 $ 2,103 Accrued other 2,293 1,236 Total accrued expenses $ 5,074 $ 3,339

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies The Company leases certain facilities, office equipment and automobiles under non-cancellable operating leases that expire on various dates through June 2022. The future minimum lease payments related to the Company’s non-cancellable operating lease commitments that have initial or remaining non-cancellable lease terms in excess of one year as of June 30, 2015 were as follows: For the Year Ending June 30, (In thousands) 2016 $ 1,237 2017 1,244 2018 1,256 2019 1,259 2020 1,283 Thereafter 2,639 $ 8,918 Rental expenses under operating leases during the years ended June 30, 2015, 2014 and 2013 were $0.9 million, $0.6 million and $0.3 million, respectively. From time to time, the Company is involved in various legal proceedings, claims, suits and complaints arising out of the normal course of business. Based on the facts currently available to the Company, management believes that these claims, suits and complaints are adequately provided for, covered by insurance, without merit or not probable that an unfavorable outcome will result. A former employee, Talbot Smith, who was terminated for cause by Unilife, filed a civil complaint in the United States District Court of the Eastern District of Pennsylvania on August 30, 2013, and an amended complaint on March 5, 2014, alleging that he was wrongly terminated in retaliation for making allegations about the Company’s compliance practices. We and various third parties, including law firms and regulatory consulting firms, investigated the allegations made by Mr. Smith and determined that his allegations were without merit, and the Company brought counterclaims against Mr. Smith. Discovery concluded and in February 2015 we filed our motions for summary judgment with the District Court, seeking entry of judgment in favor of the Company on the claims brought by Mr. Smith against the Company, and entry of judgment in favor of the Company on the claims brought by the Company against Mr. Smith. Following the discovery process and while the Company’s motions for summary judgment were pending before the District Court, on August 18, 2015, Mr. Smith dismissed his claims against the Company with prejudice. As previously disclosed, subsequent to the filing of the OSHA complaint by Mr. Smith, we received a subpoena from the staff of the U.S. Securities and Exchange Commission (the “Staff”) requesting the Company to provide certain information to the Staff, which is generally consistent with the meritless allegations made by Mr. Smith in his OSHA complaint. In his complaint filed in the United States District Court for the Eastern District of Pennsylvania, Mr. Smith stated that he provided the Staff with information about his allegations in July and August 2012. The Company responded to that subpoena and has received additional subpoenas from the Staff, requesting additional information consistent with the first subpoena. The Company is cooperating fully with the Staff and has provided the requested information. On January 8, 2014, the Company was served with a derivative complaint filed in the Delaware Chancery Court by Cambridge Retirement System, a purported stockholder of the Company, against its Board of Directors to recover allegedly “excessive and wasteful” compensation paid to the non-executive directors since 2010. The Company believes that these allegations are baseless and without merit and the Company and the directors are defending themselves vigorously. In February 2014, the Company filed a motion to dismiss the complaint in lieu of an answer. On June 26, 2014, the Court granted the Company’s motion to dismiss with respect to the directors’ equity grants, but denied the motion with respect to their cash compensation. The Company filed an answer to the remaining claims on July 11, 2014. On June 4, 2015, the parties entered into a Memorandum of Understanding agreeing to the basic terms of a non-monetary settlement of the action. The parties are negotiating the final terms of a stipulated settlement to be submitted to the Court for approval. The Company does not believe there will be any material impact to the Company or its business as a result of the SEC or Cambridge Retirement Fund matters.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Long-Term Debt	9. Long-Term Debt Long-term debt consists of the following: June 30, 2015 2014 (In thousands) 10.25% term loan, due March 2020 $ 55,518 $ 33,457 Amended Royalty Agreement liability 9,930 6,400 6.00% mortgage loans, due December 2031 12,812 13,228 5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021 2,033 2,087 Other 142 276 80,435 55,448 Less: current portion of long-term debt 775 613 Total long-term debt $ 79,660 $ 54,835 Term Loan On March 12, 2014, (the “Closing Date”), the Borrower entered into a credit agreement with the Lender. Pursuant to and subject to the terms of the credit agreement, the Lender agreed to provide term loans to the Borrower in the aggregate principal amount of up to $60.0 million. A first tranche loan of $40.0 million was drawn on the Closing Date and a further two tranches each of $10.0 million were committed by the Lender and were to be funded on each of December 15, 2014 and June 15, 2015, subject to and in accordance with the terms of the credit agreement. On September 30, 2014, the Borrower entered into a First Amendment to the Credit Agreement to accelerate the funding of the two additional tranches pursuant to which it received the proceeds from the first $10.0 million tranche on October 1, 2014 and the proceeds from the second $10.0 million tranche on November 10, 2014. The Loan bears interest at 9.25% per annum plus the greater of three-month LIBOR or 1.0%, payable in cash quarterly and as otherwise described in the Amended Credit Agreement. A default interest rate of 14.25% per annum plus the greater of three-month LIBOR or 1.0% shall apply during the existence of a default under the Amended Credit Agreement. The Loans will be interest-only until March 12, 2020 (the “Maturity Date”). Unless the loan facility is otherwise terminated earlier pursuant to the terms of the Amended Credit Agreement, the Borrower is required to repay in full the unpaid principal amount of the Loans drawn down, together with all accrued and unpaid interest thereon plus a 10.0% repayment premium on Maturity Date. The Borrower can make voluntary repayments at any time of any unpaid principal amount of the Loans, plus a 10.0% repayment premium. The Borrower must make mandatory prepayments in certain prescribed circumstances, including, without limitation, certain dispositions of assets and certain casualty events. In such events, the Borrower must prepay to Lender 100% of the net cash proceeds received. The obligations of the Borrower under the Amended Credit Agreement are guaranteed by the Company and each of its subsidiaries and the Amended Credit Agreement is secured by the assets of the Company and its subsidiaries. The security interests granted by Borrower, the Company, Unilife Cross Farm LLC (“Cross Farm”), Unilife Medical Solutions Limited (“USML”) and Unitract Syringe Pty Limited (“Unitract Syringe”) are evidenced by, among other things, the Pledge and Security Agreement, dated as of March 14, 2014, by the Borrower, the Company, Cross Farm, USML, and Unitract Syringe in favor of Lender, for itself and as agent for Royalty Opportunities S.A.R.L. (“ROS”), the Mortgage and Security Agreement, dated March 12, 2014, by and between Cross Farm and Lender, for itself and as agent of ROS, and the General Security Deed, dated as of March 12, 2014, by Unitract Syringe, USML, and the Company in favor of the Lender, for itself and as agent of ROS. The Amended Credit Agreement also contains certain customary covenants, as well as covenants relating to achieving minimum cash revenue targets at the end of each calendar year, maintaining a minimum liquidity target of $5.0 million, and the execution of certain customer and employment agreements in form and substance satisfactory to lender. In the event of default, Borrower must prepay to Lender any unpaid principal amount of the loans drawn down, together with all accrued and unpaid interest thereon plus a 10.0% repayment premium. An event of default could also result in the Lender enforcing its security over the assets of Borrower, the Company, Cross Farm, UMSL and Unitract Syringe in accordance with the terms of the OrbiMed Credit Agreement and the related security agreements. On June 30, 2015, the Company entered into a Second Amendment to the Credit Agreement to remove the minimum cash revenue target for the six month period ended June 30, 2015. As of and for the year ended June 30, 2015, the Company is in compliance with all the loan covenants set forth in the Amended Credit Agreement. However, there can be no assurance that the Company will be able to maintain the minimum liquidity target or achieve the minimum cash revenue covenants during the 12-month period from June 30, 2015. In connection with the credit agreement, the Borrower entered into a royalty agreement (the “Royalty Agreement”) with ROS which will entitle ROS to receive royalty payments. Concurrent with the First Amendment to the Credit Agreement, the Borrower entered into the First Amendment to the Royalty Agreement (the “Amended Royalty Agreement”). Pursuant to and subject to the terms of the Amended Royalty Agreement, Borrower has agreed to pay the Lender 3.875% on the first $50.0 million of net sales (on a cash receipts basis as defined in the Amended Credit Agreement) in each fiscal year, plus 1.500% of net sales in excess of $50.0 million and up to and including $100.0 million in each fiscal year, plus 0.375% of net sales in excess of $100.0 million in each fiscal year. Borrower has the right to buyout the Amended Royalty Agreement at any time on or before March 12, 2018 at a reduced amount. The lender has the right to exercise a put option upon the occurrence of an event of default upon which the Borrower would be required to pay the buyout amount under the Amended Royalty Agreement. The buy-out amount ranges from $9.75 million to $26.25 million (such amount to be determined based on when the buy-out or put option is exercised), less amounts previously paid by Borrower to Lender pursuant to the Amended Royalty Agreement. The Amended Royalty Agreement has a term commencing on the Closing Date and ending on the earlier of (i) the tenth anniversary of the Closing Date and (ii) the date of payment of the purchase price pursuant to the exercise of a put option by the Lender or the exercise of a buy-out option by the Borrower. As the Company has elected to value the Amended Royalty Agreement at fair value, the put option feature does not meet the criterion of ASC 815-15-25-1b and thus is not separated from the host contract and accounted for as a derivative instrument. The Company determined that the Amended Credit Agreement and the Amended Royalty Agreement should be accounted for as two separate units. Accordingly, the Company allocated the proceeds from the Loans on a residual basis between the two units based on their relative fair values. As a result, on the Closing Date, the royalty liability was determined to have a fair value of $7.0 million and the Loan was allocated the remaining proceeds of $33.0 million. The $20.0 million from the two additional tranches that were funded during the three months ended December 31, 2014 was reflected as incremental debt. The Loan will be accreted to the face value over the loan term based on the effective interest rate. The royalty liability will be adjusted to fair value on a quarterly basis. As of June 30, 2015, the fair value of the royalty liability was $9.9 million. There are cross-defaults in the Amended Credit Agreement, Metro Bank Loan and Keystone/CFA Loan, so that a default under one agreement could trigger a default under the others. Metro Bank, the Lender under the Amended Credit Agreement, Keystone Redevelopment Group, LLC and Commonwealth Financing Authority are parties to an intercreditor agreement. Mortgage Loans In October 2010, Cross Farm entered into the Loan Agreement with Metro Bank, pursuant to which Metro Bank provided Cross Farm with two mortgage loans in the amounts of $14.25 million (“First Mortgage”) and $3.75 million (“Second Mortgage”). The proceeds received were used to finance the purchase of land and construction of the Company’s corporate headquarters and manufacturing facility in York, Pennsylvania. In connection with the credit agreement, the Company entered into the Metro Bank Amendment pursuant to which the Second Mortgage due October 2020 was repaid. Cross Farm is paying principal and interest on the First Mortgage, with interest at a fixed rate of 6.00%. The original Metro Bank loan documents contain certain customary covenants, including the maintenance of a debt service reserve account in the amount of $2.4 million, classified as restricted cash on the consolidated balance sheet, which will remain in place until Cross Farm and Metro agree on the financial covenants. In addition the Company is required to maintain a cash balance of $5.0 million inclusive of the $2.4 million reserve account. The terms of the original Metro Bank loan documents allow the Company to use the debt service reserve account to pay monthly debt service on the mortgage loans, so long as the balance in the account is at least $1.6 million and is replenished to $2.4 million every six months. The Company is in compliance with its debt covenants as of and for the year ended June 30, 2015. However, there can be no assurance that the Company will be able to maintain the debt service reserve account balance for a period of 12 months from June 30, 2015. Cross Farm may prepay the loan without penalty. The U.S. Department of Agriculture has guaranteed $8.0 million of the mortgage loan due December 2031. In connection with the First Mortgage, the Company has given Metro Bank a lien on the building and real estate and the debt service reserve account. Secured Lending Facility In August 2011, the Company entered into a Master Lease Agreement (the “Lease Agreement”) with Varilease Finance, Inc. (“Varilease”) for up to $10.0 million of secured financing for production equipment for its Unifill syringe. Based on the Company’s continuing involvement throughout the term of the agreement and the integral nature of the production equipment, the transaction was being accounted for as a financing. Over the term of the Lease Agreement, the Company made 27 monthly installments based upon the amount drawn. This facility had an effective interest rate of 14.00%. The secured lending facility contained covenants and provisions for events of default customarily found in lease agreements. As previously disclosed on September 30, 2013, Varilease and CCA Financial LLC (collectively, the “Lessors”) filed an action in the State of Michigan in the Circuit Court for the County of Oakland, Case No. 2013-136458-CK seeking a judgment confirming the terms of the lease. The Company removed the action to the U.S. District Court for the Eastern District of Michigan, Case No. 2:13-CV-14238-SFC-LJM, on October 4, 2013. Under the Lease Agreement, Lessors and the Company were to negotiate a buyout rate at the end of the two-year lease term, which Lessors represented to the Company during the lease negotiations would be 15% of the amount financed. When the Company notified Lessors that it wanted to exercise the buyout of the equipment, Lessors claimed a buyout rate significantly higher than 15%. Under the terms of the lease, if the parties were unable to agree on a buyout rate by the end of the lease term, the lease would automatically renew for an additional 12-month period and the Company would be responsible for another year of lease payments. Lessor’s action in Michigan state court asked the court to confirm that the parties were unable to agree on a buyout rate and therefore under the terms of the lease the lease was automatically extended for one year. As previously disclosed, the Company also filed suit on September 30, 2013 against Lessors in the U.S. District Court for the Eastern District of Michigan, Case No. 2:13-cv-14174-SFC-LJM alleging, among other things, that Lessors fraudulently induced the Company into entering the lease by making misrepresentations about the buyout rate. The Company sought, among other things, to have the federal court enforce a 15% buyout rate and to enjoin Lessors from declaring a default under the lease and taking possession of the equipment for which the Company would have to impair the carrying value of assets. On October 17, 2013, in a stipulated order, the U.S. District Court ordered that the Company continue to make the same monthly payments under the lease, which as long as the Company made timely payments, Lessors shall not declare a default, and that Lessors were required to provide advance notice of a default. As previously disclosed, the Company entered into a Confidential Mutual Release and Settlement Agreement (the “Definitive Settlement Agreement”), effective December 30, 2013, with the Lessors. The Definitive Settlement Agreement provided that it will obtain title to all equipment under the equipment lease upon the payment to the Lessors of approximately $4.8 million over the next twelve months. In addition, under the Definitive Settlement Agreement the Company and the Lessors released each other from any and all claims related to the companion lawsuits, as well as dismissed such lawsuits. In connection with the Definitive Settlement Agreement, during the year ended June 30, 2014, the Company recognized $3.6 million of interest expense representing the difference between the carrying value of the debt and the present value of the settlement amount. During the year ended June 30, 2014, the Company paid $4.7 million (including $3.5 million with proceeds from the March 12, 2014 Credit Agreement) to the Lessors in satisfaction of the Company’s remaining obligations under the Definitive Settlement Agreement. Effective March 12, 2014 the Lessors released all liens and security interest in all of the Company’s assets subject to the Lease Agreement. Commonwealth of Pennsylvania Financing Authority Loan In December 2010, Cross Farm received a $2.25 million loan from the Commonwealth of Pennsylvania for land and the construction of its current manufacturing facility. The loan bears interest at a rate of 5.00% per annum, matures in January 2021 and is secured by a third mortgage on the facility. In connection with the loan agreement, Cross Farm entered into an intercreditor agreement by which the Commonwealth of Pennsylvania agreed that it would not exercise its rights in the event of a default by Cross Farm without the consent of Metro Bank, which holds the first mortgage on the facility. As of June 30, 2015, aggregate maturities of long-term obligations are as follows: For the Year Ending June 30, (In thousands) 2016 $ 775 2017 552 2018 584 2019 618 2020 65,853 Thereafter 12,053 $ 80,435

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The Company’s net loss per share is as follows: Years Ended June 30, 2015 2014 2013 (In thousands, except share and per share data) Numerator Net loss $ (90,849 ) $ (57,899 ) $ (63,198 ) Denominator Weighted average number of shares used to compute basic net loss per share 112,194,900 98,062,664 81,165,773 Effect of dilutive options to purchase common stock — — — Weighted average number of shares used to compute diluted net loss per share 112,194,900 98,062,664 81,165,773 Basic and diluted net loss per share $ (0.81 ) $ (0.59 ) $ (0.78 ) Due to the Company’s net losses, unvested shares of restricted stock (participating securities) totaling 6,990,214, 2,687,775 and 4,909,091 were excluded from the calculation of basic and diluted net loss per share during the years ended June 30, 2015, 2014 and 2013, respectively. In addition, stock options (non-participating securities) totaling 3,500,596, 4,642,725, and 7,996,935 during the years ended June 30, 2015, 2014 and 2013, respectively, were excluded from the calculation of diluted net loss per share as their effect would have been anti-dilutive. Certain of these stock options were excluded solely due to the Company’s net loss position. Had the Company reported net income during the years ended June 30, 2015, 2014 and 2013, these shares would have had an effect of 145,735, 323,854, and 595,550 diluted shares, respectively, for purposes of calculating diluted net loss per share.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes For the years ended June 30, 2015, 2014 and 2013, income (loss) before income taxes consists of the following: Years Ended June 30, 2015 2014 2013 (In thousands) Domestic $ (89,617 ) $ (58,784 ) $ (63,752 ) International (1,232 ) 885 554 $ (90,849 ) $ (57,899 ) $ (63,198 ) Tax Rate Reconciliation Income tax expense (benefit) is as follows: Years Ended June 30, 2015 2014 2013 Current Deferred Total Current Deferred Total Current Deferred Total (In thousands) U.S. Federal $ — $ (27,385 ) $ (27,385 ) $ — $ (18,415 ) $ (18,415 ) $ — $ (21,188 ) $ (21,188 ) State — (8,684 ) (8,684 ) — (5,839 ) (5,839 ) — (6,226 ) (6,226 ) International — (369 ) (369 ) — 266 266 — 177 177 Changes in valuation allowance — 36,438 36,438 — 23,988 23,988 — 27,237 27,237 Income tax provision $ — $ — $ — $ — $ — $ — $ — $ — $ — Income tax expense (benefit) was $0 for the years ended June 30, 2015, 2014 and 2013 and differed from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) as a result of the following: Years Ended June 30, 2015 2014 2013 Tax at U.S. statutory rate (35 )% (35 )% (35 )% State taxes, net of federal benefit (6 )% (6 )% (10 )% Non-deductible and non-taxable items 1 % — 1 % Change in valuation allowance 40 % 41 % 44 % 0 % 0 % 0 % Significant Components of Deferred Taxes The tax effects of temporary differences and net operating losses that give rise to significant portions of deferred tax assets (liabilities) at June 30, 2015 and 2014 are presented below: June 30, 2015 2014 (In thousands) Net operating loss carryforwards $ 110,876 $ 89,362 Share-based compensation expense 20,548 16,532 Deferred revenue 6,951 — Depreciation differences 4,324 2,399 Accruals/Reserves 3,517 2,104 Valuation allowance (146,216 ) (110,397 ) Net deferred taxes $ — $ — The valuation allowance for deferred tax assets as of June 30, 2015 and 2014 was $146.2 million and $110.4 million, respectively. The net change in the total valuation allowance was an increase of $35.8 million. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible or prior to the expiration of the net operating loss carryforwards. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax-planning strategies in making the assessment as to the realizability of deferred tax assets. Based upon the level of historical taxable income and uncertainty regarding projections for future taxable income over the periods in which the deferred tax assets are deductible or can be utilized, management does not believe it is more likely than not that the Company will realize the benefits of these net operating losses and deductible temporary differences, as of June 30, 2015 and 2014. Therefore, a full valuation allowance has been provided as of June 30, 2015 and 2014. The amount of the net deferred tax assets considered realizable; however, could change if estimates of future taxable income during the carryforward period are increased. As of June 30, 2015, the Company had net operating loss carryforwards for U.S federal, state and Australian income tax purposes of approximately $256.4 million, $256.4 million and $22.7 million, respectively, which are available to offset future taxable income. The U.S. federal and state net operating loss carryforwards begin to expire in 2023. The Australian net operating losses do not expire. The Australian net operating loss carryforwards of approximately $22.7 million as of June 30, 2015 are subject to either the continuity of ownership or same business test (as defined under Australian tax law) that could limit or substantially eliminate the Company’s ability to use these carryforwards. If there have been or will be changes in the Company’s ownership or Australian business operations before these net operating loss carryforwards are utilized, they may be unavailable to reduce taxable income in the future. Further, under provision of the Internal Revenue Code, the utilization of a U.S corporation’s federal and state net operating loss carryforwards may be significantly limited following a change in ownership of greater than 50% within a three-year period. The Company’s federal and state net operating loss carryforwards may, therefore, be subject to an annual limitation. In addition, state net operating loss carryforwards may be further limited in Pennsylvania, which has a limitation equal to the greater of 20% of taxable income after modifications and apportionment, or $5.0 million on state net operating losses utilized in any one year. Management has evaluated the tax positions taken and has concluded that no liability for unrecognized tax benefits was required to be recorded for the years ended June 30, 2015, 2014 and 2013. The Company files Australian, U.S. federal and state income tax returns. The Company is not subject to examination in any jurisdiction at this time. As a result of the net operating losses in prior years, the statute of limitations will remain open for a period following any utilization of net operating loss carryforwards and as such these periods remain subject to examination.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jun. 30, 2015
Postemployment Benefits [Abstract]
Employee Benefit Plan	12. Employee Benefit Plan The Company has a retirement savings 401(k) plan covering all U.S. employees (the “Plan”). Participating employees may contribute up to 100% of their pre-tax earnings, subject to the statutory limits. Effective January 1, 2012, the Company began a discretionary match to participant contributions into the Plan. The Company contributes fifty cents for each dollar a participant contributes, with a maximum of 3% of a participant’s eligible earnings. The contributions made by the Company vest 50% upon two years of service and 100% upon three years of service. During the years ended June 30, 2015, 2014 and 2013, the Company paid $0.5 million, $0.3 million and $0.3 million, respectively, to match employee contributions. Additionally, during the years ended June 30, 2015 and 2013, the Company made a discretionary contribution of 1% of compensation, as defined, to all eligible employees, which amounted to $0.1 million and $0.1 million, respectively. During the year ended June 30, 2014, the Company did not make any discretionary contributions.

Revenue

Revenue	12 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Revenue	13. Revenue The Company recognized $13.2 million, $14.7 million and $2.7 million of revenue during the years ended June 30, 2015, 2014 and 2013, respectively. During the year ended June 30, 2015, three customers accounted for 35%, 32% and 24% of consolidated revenue, respectively. During the year ended June 30, 2014, three customers accounted for 34%, 23% and 15% of consolidated revenue, respectively. During the year ended June 30, 2013, one customer accounted for 96% of consolidated revenue. During the year ended June 30, 2015, revenue attributed to France accounted for 24% of consolidated revenue. During the year ended June 30, 2014, revenue attributed to Jordan and France accounted for 34% and 15% of consolidated revenue, respectively. During the year ended June 30, 2013, revenue attributed to France accounted for 96% of consolidated revenue. During the year ended June 30, 2015, the Company recognized $5.1 million of revenue related to substantive milestones, as follows: The Company recognized $2.7 million of revenue during the year ended June 30, 2015 pursuant to a feasibility agreement with a customer related to substantive milestones that were completed and accepted during the year. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon substantive milestones. An initial up-front payment of $0.1 million was determined to be non-substantive and is being recognized on a straight-line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the year ended June 30, 2015 were as follows: • $0.4 million for development and delivery of a detailed project plan and a failure mode and effects analysis report; • $0.4 million for development and delivery of a report on preliminary product requirements and a risk management plan; • $1.5 million for development and delivery of human factor stimuli and related supporting documents; and • $0.4 million for development and delivery of additional human factor stimuli. The remaining substantive milestones as of June 30, 2015 are as follows: • $0.5 million for development and delivery of additional human factor stimuli and a report on updated product requirements; and • $1.2 million for development and delivery of semi-functional prototypes and related feasibility, product requirement, and risk management reports. The Company recognized $0.9 million of revenue during the year ended June 30, 2015 pursuant to a feasibility agreement with a customer related to substantive milestones that were completed and accepted during the year. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon milestones. An initial up-front payment of $0.5 million was determined to be non-substantive and is being recognized on a straight-line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the year ended June 30, 2015 were as follows: • $0.5 million for development and delivery of a report on device design options as well as potential manufacturing and assembly processes; and • $0.4 million for development and delivery of product samples and related supporting documents. The remaining substantive milestone as of June 30, 2015 is as follows: • $0.2 million for development and delivery of a summary report related to testing and documentation activities. The Company recognized $0.3 million of revenue during the year ended June 30, 2015 pursuant to a feasibility agreement with a customer related to substantive milestones that were completed and accepted during the year. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon milestones. The milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the year ended June 30, 2015 were as follows: • $0.1 million for development and delivery of a report related to human factor studies and quality requirements; • $0.1 million for development and delivery of devices for compatibility and stability functional testing and related reporting; and • $0.1 million for development and delivery of devices for human factor study and related reporting. There are no remaining substantive milestones under this agreement. The Company recognized $0.2 million of revenue during the year ended June 30, 2015 pursuant to a feasibility agreement with a customer related to substantive milestones that were completed and accepted during the year. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon milestones. The milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the year ended June 30, 2015 were as follows: • $0.1 million for development of customized devices for testing; and • $0.1 million for development and delivery of testing activities and related reporting. There are no remaining substantive milestones under this agreement. The Company recognized $1.0 million of revenue during the year ended June 30, 2015 pursuant to a master services and supply agreement with a customer related to substantive milestones that were completed and accepted during the year. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon substantive milestones. An initial up-front payment of $1.1 million was determined to be non-substantive and is being recognized on a straight-line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the year ended June 30, 2015 were as follows: • $0.2 million for development and delivery of a report defining device requirements; • $0.2 million for development and delivery of a report defining system requirements; • $0.2 million for development and delivery of devices for testing; • $0.2 million for development and delivery of a report defining production requirements; and • $0.2 million for development and delivery of components for a human factor study. The remaining substantive milestones as of June 30, 2015 are as follows: • $0.6 million for development and delivery of a complete system layout; • $0.3 million for development and delivery of components for a human factor study; • $0.6 million for development and delivery of feasibility devices for testing; • $0.6 million for development and delivery of a clinical production process; • $0.4 million for development and delivery of components for a human factor study; • $0.4 million for completion of testing of assembly equipment; • $0.3 million for completion of filling process of clinical devices; • $0.4 million for delivery of containers for the filling process; and • $0.3 million for delivery of devices for clinical studies. During the year ended June 30, 2015, the Company recognized $8.1 million of revenue related to services rendered on a time and materials basis, proportional performance method and/or straight-line basis over the requisite service period pursuant to customer agreements to provide various customization and development services. During the year ended June 30, 2014, the Company recognized $8.1 million of revenue related to substantive milestones, as follows: The Company recognized $1.3 million of revenue during the year ended June 30, 2014 pursuant to a clinical supply agreement with a customer related to substantive milestones that were completed and accepted during the year. This agreement provides for the customization and development activities for a drug delivery system for a customer and provides for payments to be made upon the completion of agreed-upon milestones. The milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the year ended June 30, 2014 were as follows: • $0.4 million for development and delivery of devices to be used by the customer for compatibility testing; • $0.1 million for delivery of development and testing activities; • $0.6 million for delivery of development, testing and verification activities; • $0.1 million for development and delivery of testing materials; and • $0.1 million for certain support and testing activities. There are no remaining substantive milestones under this agreement. The Company recognized $0.8 million of revenue during the year ended June 30, 2014 pursuant to a customization and commercial supply agreement with a customer related to a substantive milestone that was completed during the year. This agreement provides for the development of customized component parts for the customer to use in a drug-device combination product and provides for payments to be made upon the completion of agreed-upon milestones. The milestones were determined to be substantive at the time the agreement was entered into. The substantive milestone achieved during the year ended June 30, 2014 were as follows: • $0.8 million for customization and delivery of devices for compatibility and initial evaluation testing. The remaining substantive milestones were as follows: • $0.8 million for delivery of devices for regulatory filings; and • $0.2 million for certain delivery of services supporting the customer’s regulatory approval process. The Company recognized $0.7 million of revenue during the year ended June 30, 2014 pursuant to a materials transfer agreement with a customer related to substantive milestones that were completed during the year. This agreement provides for certain materials and related services to the customer and provides for payments to be made upon the completion of agreed-upon milestones. The milestones were determined to be substantive at the time the agreement was entered into. The substantive milestones achieved during the year ended June 30, 2014 were as follows: • $0.4 million for delivery of testing materials; • $0.1 million for delivery of device design requirements report; and • $0.2 million for delivery of customization activities. There were no remaining substantive milestones under this agreement. The Company recognized $0.3 million of revenue during the year ended June 30, 2014 pursuant to a collaborative research agreement with a customer related to substantive milestones that were completed during the year. This agreement provides for certain materials and related services to the customer and provides for payments to be made upon the completion of agreed-upon milestones. The milestones were determined to be substantive at the time the agreement was entered into. The substantive milestones achieved during the year ended June 30, 2014 were as follows: • $0.1 million for customization and delivery of devices for evaluation and user study purposes; and • $0.2 million for customization and delivery of devices for evaluation activities. There were no remaining substantive milestones under this agreement. The Company recognized $5.0 million of revenue during the year ended June 30, 2014 pursuant to a binding license, development and supply agreement with a customer related to a substantive milestone that was completed during the year. This agreement provides for the development of customized devices and drug delivery systems for the customer to use in a drug-device combination product and provides for payments to be made upon the completion of agreed-upon milestones. The milestones were determined to be substantive at the time the agreement was entered into. The substantive milestone achieved during the year ended June 30, 2014 was as follows: • $5.0 million for customization, design and production of a prototype device for incorporation into a drug delivery system. The remaining substantive milestones were as follows: • $5.0 million for delivery and acceptance of application for regulatory approval; and • $1.0 million each upon regulatory approval for up to 20 drug-delivery device combination products. During the year ended June 30, 2014, the Company recognized $4.3 million in revenue related to services rendered on a time and materials basis during the period pursuant to customer agreements to provide various customization and development services. During the year ended June 30, 2014, the Company recognized the final $2.3 million of revenue related to its licensing agreement with Sanofi. During the year ended June 30, 2013, the Company recognized $2.6 million of revenue related to its licensing agreement with Sanofi and $0.1 million from other sales.

Financial Instruments

Financial Instruments	12 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Financial Instruments	14. Financial Instruments The Company does not hold or issue financial instruments for trading purposes. The estimated fair values of the Company’s financial instruments are as follows: June 30, 2015 June 30, 2014 Carrying Estimated Carrying Estimated (In thousands) Amended Royalty Agreement liability $ 9,930 $ 9,930 $ 6,400 $ 6,400 The carrying amount of the Company’s cash equivalents, which includes certificates of deposit, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short term maturities of these items. The estimated fair value of the Company’s debt approximates its carrying value based upon the rates that the Company would currently be able to receive for similar instruments of comparable maturity. The Company categorizes its assets and liabilities measured at fair value into a fair value hierarchy that prioritizes the inputs used in pricing the asset or liability. The three levels of the fair value hierarchy are as follows: Level 1 Level 2 Level 3 The levels in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The following table presents the Company’s liabilities that are measured at fair value on a recurring basis for the periods presented: Fair Value Based On Quoted Market Significant Significant Total (In thousands) Amended Royalty Agreement liability: June 30, 2015 $ — $ — $ 9,930 $ 9,930 June 30, 2014 $ — $ — $ 6,400 $ 6,400 The following table presents the changes in the fair value of the level 3 financial instruments for the years ended June 30, 2015 and 2014. Royalty June 30, 2013 $ — Allocation of initial proceeds 7,000 Decrease in royalty liability (600 ) June 30, 2014 $ 6,400 Royalty payments (749 ) Increase in royalty liability 4,279 June 30, 2015 $ 9,930 Following is a description of the valuation methodology used to measure the Amended Royalty Agreement liability at fair value. There have been no changes in the methodology used during the year ended June 30, 2015: The fair value is based on a discounted cash flow methodology under the income approach based on the present value sum of payments expected to be made in the future. The fair value is estimated by applying a risk adjusted discount rate to the expected royalty payment stream. These fair value estimates are most sensitive to changes in the payment stream and royalty rates.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions The Company has an agreement with a consulting firm, of which a member of the Company’s board of directors is the principal. Under the terms of the agreement, the Company pays a fee for finance, accounting and secretarial consulting services within Australia. Amounts paid to the consulting entity during the years ending June 30, 2015, 2014 and 2013 were $0.2 million, $0.2 million and $0.2 million, respectively.

Quarterly Results (unaudited)

Quarterly Results (unaudited)	12 Months Ended
	Jun. 30, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results (unaudited)	16. Quarterly Results (unaudited) Quarter Ended Quarter Ended Quarter Ended Quarter Ended (In thousands, except per share data) Year Ended June 30, 2015 Revenues $ 1,380 $ 5,403 $ 2,921 $ 3,454 Gross profit 1,380 5,403 2,921 3,454 Net loss (22,262 ) (19,387 ) (23,105 ) (26,095 ) Basic and diluted loss per share $ (0.21 ) $ (0.18 ) $ (0.20 ) $ (0.22 ) Quarter Ended Quarter Ended Quarter Ended Quarter Ended (In thousands, except per share data) Year Ended June 30, 2014 Revenues $ 3,187 $ 3,573 $ 1,383 $ 6,546 Gross profit 3,187 3,573 1,383 6,546 Net loss (11,244 ) (16,283 ) (15,109 ) (15,263 ) Basic and diluted loss per share $ (0.12 ) $ (0.17 ) $ (0.15 ) $ (0.15 ) Per share amounts for the quarters may not add to the annual amount due to differences in the weighted average common shares outstanding during the period.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On July 29, 2015, the Company entered into the New Sales Agreement with Cantor, pursuant to which it may, from time to time, issue and sell shares of common stock through Cantor as its sales agent, having an aggregate offering price of up to $25.0 million, subject to certain limitations and conditions set forth in the New Sales Agreement. Under the New Sales Agreement, Cantor may sell the shares by any method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, but not limited to, sales made directly on The NASDAQ Global Market, on any other existing trading market for the shares or to or through a market maker. Cantor has agreed in the new Sales Agreement to use its commercially reasonable efforts to sell the shares in accordance with the Company’s instructions (including any price, time or size limit or other customary parameters or conditions the Company may impose). The Company is not obligated to make any sales of the shares under the New Sales Agreement. The Company will pay Cantor a commission of up to 3.0% of the gross sales price per share sold and has agreed to provide Cantor with customary indemnification and contribution rights. Through September 14, 2015, the Company has issued 2,870,689 shares for net proceeds of $3.8 million under the Sales Agreement. On July 29, 2015, the Company entered into the Purchase Agreement with LPC, pursuant to which it has the right to sell, from time to time, to LPC up to $45.0 million in shares of the Company’s common stock through July 2017, subject to certain limitations and conditions set forth in the Purchase Agreement. During July 2015, LPC purchased $5.0 million in shares of common stock. The Company received net proceeds of approximately $4.8 million after expenses. Following the initial purchase, on any business day and as often as every other business day over the 24-month term of the Purchase Agreement, and up to an aggregate amount of an additional $40.0 million (subject to certain limitations) of shares of Common Stock, the Company has the right, from time to time, at its sole discretion and subject to certain conditions to direct LPC to purchase up to 200,000 shares of Common Stock (not to exceed $2.0 million in total purchase proceeds per purchase date). The purchase price of shares of Common Stock pursuant to the Purchase Agreement will be based on the prevailing market price at the time of sale as set forth in the Purchase Agreement. The Company will control the timing and amount of any sales of Common Stock to LPC. In addition, the Company may direct LPC to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the Common Stock is not below the “threshold price” as set forth in the Purchase Agreement. The Purchase Agreement contains customary representations, warranties and agreements of the Company and LPC, limitations and conditions to completing future sale transactions, indemnification rights and other obligations of the parties. There is no upper limit on the price per share that LPC could be obligated to pay for Common Stock under the Purchase Agreement. The Company has the right to terminate the Purchase Agreement upon one business days’ notice, at no cost or penalty. Actual sales of shares of Common Stock to LPC under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions, the trading price of the Common Stock and determinations by the Company as to other available and appropriate sources of funding for the Company. As consideration for entering into the Purchase Agreement, the Company issued to LPC 451,354 shares of Common Stock. The Company did not receive any cash proceeds from the issuance of these shares. On September 2, 2015, the Company announced that is has engaged Morgan Stanley & Co. LLC to conduct a review of strategic alternatives to maximize shareholder value in response to third party initiated expressions of interest. Potential strategic alternatives to be explored and evaluated during the review process may include a possible sale of the Company, a strategic partnership with one or more parties or the licensing of some of the Company’s proprietary technologies. The Company will not provide any commitment regarding when or if this strategic review process will result in any type of transaction and no assurance can be given that the Company will determine to pursue a potential sale, strategic partnership or licensing arrangement. On September 14, 2015, the Company implemented a cost reduction and business realignment initiative pursuant to which the Company reduced its headcount by approximately 50 employees, or 17% of its workforce, and expects to significantly reduce its operating expenses in fiscal year 2016. In connection with this initiative, the Company expects to incur a charge of approximately $0.4 million to operating expenses in the three month period ending September 30, 2015.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All significant intercompany accounts and transactions have been eliminated in consolidation. On January 27, 2010, Unilife became the parent company of UMSL upon completion of the redomiciliation under Australian law and UMSL’s stockholders and option holders exchanged their interests in UMSL for equivalent interests in Unilife. References to the “Company” include Unilife Corporation and its consolidated subsidiaries, including UMSL, unless the context otherwise requires. References to “Unilife” are references solely to Unilife Corporation. References to A$ mean the lawful currency of the Commonwealth of Australia. References to € or euros are to the lawful currency of the European Union.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition, royalty liability valuation and share-based compensation expense. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist primarily of cash on hand, deposits at banks and other short-term highly liquid investments with original maturities of three months or less. Cash equivalents are stated at cost, which approximates fair value.
Accounts Receivable	Accounts Receivable Accounts receivable are stated at amounts due from customers, which also represents the net realizable amount. The Company evaluates the collectability of its accounts receivable on a periodic basis and has historically not recorded an allowance for doubtful accounts. In instances in which management becomes aware of circumstances that may impair a particular customer’s ability to meet its obligation, the related receivable would be written off.
Inventories	Inventories Inventories consist primarily of raw materials. Inventories are stated at the lower of cost or market, with cost determined using the first in, first out method. The Company routinely reviews its inventory for obsolete, slow moving or otherwise impaired inventory and records estimated impairments in the periods in which they occur.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment, including significant improvements, are recorded at cost, net of accumulated depreciation and amortization. Repairs and maintenance are expensed as incurred. Depreciation and amortization expense is recorded on a straight-line method over the estimated useful life of the asset as listed below: Asset Category Useful Lives Building 40 years Machinery and equipment 2 to 15 years Computer software 3 to 7 years Furniture and fixtures 3 to 7 years Leasehold improvements Shorter of leasehold improvement life or remaining term of lease Interest cost incurred in connection with the development and construction of significant new machinery and equipment, as well as facility related costs have been capitalized as one of the elements of cost and are being amortized over the asset’s respective useful life. Interest capitalized during the year ended June 30, 2015 was $2.2 million. There was no capitalized interest during the years ended June 30, 2014 or 2013. The Company evaluates the recoverability of the recorded value of long-lived assets periodically to determine if facts and circumstances exist that would indicate that the assets might be impaired or that the useful lives should be modified. As part of this valuation, the Company develops projections of undiscounted future cash flows of the asset or asset group. The projections of undiscounted cash flows include a combination of revenue from customization and development activities, capital expenses that may be necessary to support projected product sales and commercial product sales. As customization and development activities are completed, commercial product sales are expected to scale-up. Expectations of future commercial product sales included in the projections used for the impairment analysis are based on customer-specific information as well as market estimates relating to the anticipated drugs and therapies being targeted for use with the Company’s products. These projections also include assumptions of future sales growth and profitability based on contracts entered into with customers as well as future contracts to be entered into based on the current discussions and negotiations with existing and prospective customers. Sales projections are based on assumptions including a transition in the market toward patient self-administration of injectable therapies as well as transitions in the market toward biological-based drugs in the pharmaceutical industry development pipeline. The Company’s future sales could also be impacted by factors such as its ability to obtain new and retain existing customers, the timing and extent of the customers’ drug development activities as well as the regulatory approval process, drug efficacy and industry acceptance of injectable therapies. If the Company’s future sales or its projections of future sales are impacted by any one or more of the preceding factors, it will reassess the recorded value of the long-lived assets. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill is the excess of purchase price over the fair value of net assets acquired in business acquisitions. Goodwill is subject to, at a minimum, an annual impairment assessment of its carrying value. Additional impairment assessments would be performed if events and circumstances warranted such additional assessments during the year. Goodwill impairment is deemed to exist if the net book value of the Company’s reporting unit exceeds its estimated fair value. Estimated fair value of the Company’s reporting unit is determined utilizing the value implied by the Company’s year-end quoted stock price. There were no impairments recorded on goodwill during the years ended June 30, 2015, 2014 or 2013. The Company has one reporting unit. The reporting unit includes its product lines, the base technology for which was obtained as part of our November 2002 acquisition of Unitract Syringe Pty Limited and the manufacturing capability which was obtained in our January 2007 acquisition of Integrated BioSciences, Inc. In estimating the reporting unit’s fair value for purposes of the fiscal year 2015 impairment assessment, management compared the carrying value of the reporting unit to the Company’s market capitalization as of June 30, 2015, which is its annual impairment testing date. The market capitalization of approximately $283.7 million, based on the quoted stock price on NASDAQ was in excess of the Company’s stockholders’ deficit of $17.9 million. Management also considered that market capitalization through early September 2015 continued to be in excess of the carrying value. Definite-lived intangible assets include patents which are amortized on a straight-line method over their estimated useful lives of 15 years and are included in other assets. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When factors indicate a possible impairment, if the sum of the estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset is less than the carrying amount of the asset, an impairment may be recognized. Measurement of an impairment loss is based on the excess of the carrying value of the asset over its fair value. There were no impairments recorded on intangible assets during the years ended June 30, 2015, 2014 or 2013.
Deferred Financing Costs	Deferred Financing Costs Deferred financing costs are included in other assets on the consolidated balance sheets and consist of costs incurred in connection with debt financings. These costs are amortized and included in interest expense over the term of the related debt using the effective interest rate method.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are recorded to the extent the Company believes they will more likely than not be realized. In making such determinations, the Company considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company’s policy is to include interest and penalties related to uncertain tax positions within the provision (benefit) for income taxes within the Company’s consolidated statements of operations and comprehensive loss.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, the Company measures fair value based on a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. The fair value hierarchy is broken down into three levels based on the source of inputs. The carrying value of financial instruments such as accounts receivable, accounts payable and accrued expenses are reasonable estimates of their fair value because of the short maturity of these items. The Company believes that the current carrying amount of its long-term debt approximates fair value because the interest rates on these instruments are similar to those rates that the Company would currently be able to receive for similar instruments of comparable maturity. The Company has elected to measure its royalty liability at fair value in accordance with ASC 825, Financial Instruments. The fair value of the royalty liability is based on significant inputs not observable in the market, which require it to be reported as a Level 3 liability within the fair value hierarchy. The valuation uses a methodology and assumptions that the Company believes would be made by a market participant. In particular, the valuation analysis uses a discounted cash flow methodology under the income approach based on the present value sum of payments to be made in the future. The fair value of the royalty liability is estimated by applying a risk adjusted discount rate to the adjusted royalty revenue stream. These fair value estimates are most sensitive to changes in the payment stream.
Share-Based Compensation	Share-Based Compensation The Company grants equity awards to its employees, directors, consultants and service providers. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants and service providers are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility.
Foreign Currency Translation	Foreign Currency Translation The Australian dollar is the functional currency for the Company’s Australian operations. Assets and liabilities denominated in foreign currencies are translated into U.S. dollars at the rate of exchange existing at the end of the period. Revenues and expenses are translated at the average exchange rates during the applicable period. Adjustments resulting from these translations are recorded in accumulated other comprehensive income within the Company’s consolidated balance sheets and will be included in income upon sale or liquidation of the foreign investment. Gains and losses from foreign currency transactions, denominated in a currency other than the functional currency, are recorded in other income within the Company’s consolidated statements of operations and comprehensive loss and aggregated less than $0.1 million for each of the years ended June 30, 2015, 2014 and 2013.
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes net loss and other comprehensive loss (income). The Company’s other comprehensive loss (income) consists only of foreign currency translation adjustments.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from industrialization and development fees, licensing fees and product sales. The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer. The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. Revenue from industrialization and development fees is recognized as services are rendered or upon achievement of the “at risk” substantive milestone events, which represent the culmination of the earnings process related to such events. Substantive milestones can include specific deliverables such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. The terms of these contracts provide for customer payments to be made as services are rendered or substantive milestones are achieved. The Company considers whether a milestone is substantive at the inception of the agreement. The consideration earned from the achievement of a milestone must meet all of the following criteria to be considered substantive: • It is commensurate with either of the Company’s performance to achieve the milestone, or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone; • It relates solely to past performance; and • It is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Payment terms are considered to be standard commercial terms. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the substantive milestone. Fees for completed, substantive milestones, which are dependent upon customer acceptance for non-refundable payment or, if paid, are refundable pending customer acceptance are recognized upon customer acceptance or the termination of refund rights.
Advertising Costs	Advertising Costs Advertising costs are expensed in the period incurred. The Company incurred total advertising costs of $0.2 million for each of the years ended June 30, 2015, 2014 and 2013.
Research and Development Costs	Research and Development Costs Research and development expenses consist primarily of payroll and related personnel expenses (including share-based compensation expense), fees paid to external service providers, costs of materials, components and supplies, costs for facilities, tooling and equipment and costs related to developing prototype products and samples used for various evaluation, testing and related activities for existing and potential customers. Research and development expenses are included in operating expenses when incurred. Research and development expenses include costs related to the ongoing development and expansion of the Company’s broad portfolio of injectable drug delivery systems as well as costs incurred in relation to customization, industrialization and development agreements with its customers. These costs are not segregated from the overall research and development costs as they are not readily distinguishable from the rest of the Company’s ongoing research and development expenses.
Interest Expense	Interest Expense The Company recognizes interest expense in the consolidated statements of operations and comprehensive loss for all debt instruments using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating the interest expense over the relevant period. The effective interest rate is the rate that exactly discounts the estimated future cash payments through the expected life of the financial instrument to the net carrying amount of the financial liability. The application of the method has the effect of recognizing expense payable on the instrument evenly in proportion to the amount outstanding over the period to maturity or repayment. In calculating the effective interest rate, the Company estimates cash flows considering all contractual terms of the financial instrument, including fees for early redemption and all other premiums and discounts.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed as net loss divided by the weighted average number of shares outstanding during the period. Diluted net earnings per share reflect the potential dilution that could occur from common stock issued through common stock equivalents. The dilutive effect of potential common stock, consisting of non-participating restricted stock and outstanding options to purchase common stock, is calculated using the treasury stock method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid, are considered participating securities and are included in the computation of net loss per share according to the two class method if the impact is dilutive. Shares of the Company’s unvested restricted stock are considered participating securities. However, in the event of a net loss, participating securities are excluded from the calculation of both basic and diluted net loss per share.
Business Segments	Business Segments The Company operates in one reportable segment, which includes the design, development and manufacture of injectable drug delivery systems. Revenues by geographic location based on location of customer are as follows: Years Ended June 30, 2015 2014 2013 (In thousands) Domestic $ 9,834 $ 5,702 $ 120 International 3,324 8,987 2,623 $ 13,158 $ 14,689 $ 2,743
Reclassifications	Reclassifications Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU 2013-11, “Income Taxes — Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ” In May 2014, FASB issued ASU 2014-09 “Revenue from Contracts with Customers”. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers” which deferred the effective date of ASU 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Early application is permitted only as of annual periods beginning after December 15, 2016, including interim reporting periods within that reporting period. With the deferral, the new standard is effective for the Company, on July 1, 2018, with early adoption permitted one year prior. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has not selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In June 2014, FASB issued ASU 2014-12 “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” which is part of ASC 718: Compensation-Stock Compensation. The guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and not be reflected in the estimate of the grant-date fair value of the award. The guidance is effective for annual periods beginning after December 15, 2015. The guidance can be applied prospectively for all awards granted or modified after the effective date or retrospectively to all awards with performance targets outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not expect a material impact on its financial condition, results of operations or cash flows from the adoption of this guidance. In August 2014, FASB issued ASU 2014-15 “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The guidance requires an entity to perform a going concern assessment by evaluating its ability to meet its obligations for a look-forward period of one year from the financial statement issuance date. Disclosures are required if it is probable an entity will be unable to meet its obligations within the look-forward period. Incremental substantial doubt disclosure is required if the probability is not mitigated by management’s plans. The guidance is effective for all entities for the first annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact this guidance will have on its financial disclosures; however, as the guidance only impacts disclosure, the adoption of this guidance is not expected to have any impact on the Company’s financial condition, results of operations and cash flows. In April 2015, FASB issued ASU 2015-03 “Simplifying the Presentation for Debt Issuance Costs”. The guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its financial statement presentation and any disclosures.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Estimated Useful Life of Asset	Depreciation and amortization expense is recorded on a straight-line method over the estimated useful life of the asset as listed below: Asset Category Useful Lives Building 40 years Machinery and equipment 2 to 15 years Computer software 3 to 7 years Furniture and fixtures 3 to 7 years Leasehold improvements Shorter of leasehold improvement life or remaining term of lease
Sales by Geographic Location	Revenues by geographic location based on location of customer are as follows: Years Ended June 30, 2015 2014 2013 (In thousands) Domestic $ 9,834 $ 5,702 $ 120 International 3,324 8,987 2,623 $ 13,158 $ 14,689 $ 2,743

Equity Transactions and Share26

Equity Transactions and Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Options Activity by Employees and Directors	The following is a summary of activity related to stock options held by employees and directors during the year ended June 30, 2015: Number of Weighted Weighted Aggregate (In thousands) Outstanding as of July 1, 2014 3,922,411 $ 4.67 Cancelled (170,257 ) 5.43 Expired (1,234,000 ) 6.38 Exercised (10,000 ) 2.33 Outstanding as of June 30, 2015 2,508,154 $ 3.78 6.4 $ — Exercisable as of June 30, 2015 1,908,154 $ 3.83 6.2 $ —
Schedule of Stock Options Activity by Persons Other than Employees and Directors	The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the year ended June 30, 2015: Number of Weighted Weighted Aggregate (In thousands) Outstanding as of July 1, 2014 2,050,000 $ 4.52 Expired (1,000,000 ) 4.86 Outstanding as of June 30, 2015 1,050,000 $ 4.20 1.3 $ 23 Exercisable as of June 30, 2015 1,050,000 $ 4.20 1.3 $ 23
Summary of Outstanding and Exercisable Stock Options Held by Employees and Directors	The following is a summary of outstanding and exercisable stock options held by employees and directors as of June 30, 2015: Outstanding Options Exercisable Options Range of Exercise Prices Outstanding Weighted Weighted Exercisable Weighted Weighted $0.00 — $5.00 2,190,000 $ 3.50 6.8 1,590,000 $ 3.46 6.6 $5.01 — $7.00 318,154 5.69 4.2 318,154 5.69 4.2 2,508,154 $ 3.78 6.4 1,908,154 $ 3.83 6.2
Summary of Outstanding and Exercisable Stock Options Held by Non-Employees and Non-Directors	The following is a summary of outstanding and exercisable stock options held by persons other than employees and directors as of June 30, 2015: Outstanding Options Exercisable Options Range of Exercise Prices Outstanding Weighted Weighted Exercisable Weighted Weighted $0.00 — $2.00 150,000 $ 2.00 0.8 150,000 $ 2.00 0.8 $2.01 — $6.00 900,000 4.57 1.4 900,000 4.57 1.4 1,050,000 $ 4.20 1.3 1,050,000 $ 4.20 1.3
Fair Value of Options and Warrants	The Company used the following weighted average assumptions in calculating the fair value of options and warrants granted during the year ended June 30, 2014 and 2013: 2014 2013 Number of stock options granted 500,000 810,000 Expected dividend yield 0 % 0 % Risk-free interest rate 1.52 % 1.03 % Expected volatility 55 % 55 % Expected life (in years) 5.5 5.44
Summary of Activity Related to Restricted Stock Awards	The following is a summary of activity related to restricted stock awards during the year ended June 30, 2015: Number of Weighted Average Unvested as of July 1, 2014 2,436,061 $ 3.42 Granted 9,507,434 2.83 Vested (947,344 ) 3.54 Cancelled (264,375 ) 3.42 Unvested as of June 30, 2015 10,731,776 $ 2.89

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Components of Property, Plant and Equipment	Property, plant and equipment consist of the following: June 30, 2015 2014 (In thousands) Building $ 32,359 $ 32,188 Machinery and equipment 27,530 21,224 Computer software 2,910 2,675 Furniture and fixtures 1,345 610 Construction in progress 17,601 9,119 Land 2,036 2,036 Leasehold improvements 270 166 84,051 68,018 Less: accumulated depreciation and amortization (17,903 ) (13,430 ) Property, plant and equipment, net $ 66,148 $ 54,588

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill during the years ended June 30, 2014 and 2015 are as follows: (In thousands) Balance as of July 1, 2013 $ 11,498 Foreign currency translation 332 Balance as of June 30, 2014 11,830 Foreign currency translation (2,145 ) Balance as of June 30, 2015 $ 9,685

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses	Accrued expenses consist of the following: June 30, 2015 2014 (In thousands) Accrued payroll and other employee related expenses $ 2,781 $ 2,103 Accrued other 2,293 1,236 Total accrued expenses $ 5,074 $ 3,339

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments Related to the Company's Non-cancellable Operating Lease Commitments	The future minimum lease payments related to the Company’s non-cancellable operating lease commitments that have initial or remaining non-cancellable lease terms in excess of one year as of June 30, 2015 were as follows: For the Year Ending June 30, (In thousands) 2016 $ 1,237 2017 1,244 2018 1,256 2019 1,259 2020 1,283 Thereafter 2,639 $ 8,918

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Components of Long-Term Debt	Long-term debt consists of the following: June 30, 2015 2014 (In thousands) 10.25% term loan, due March 2020 $ 55,518 $ 33,457 Amended Royalty Agreement liability 9,930 6,400 6.00% mortgage loans, due December 2031 12,812 13,228 5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021 2,033 2,087 Other 142 276 80,435 55,448 Less: current portion of long-term debt 775 613 Total long-term debt $ 79,660 $ 54,835
Aggregate Maturities of Long-term Obligations	As of June 30, 2015, aggregate maturities of long-term obligations are as follows: For the Year Ending June 30, (In thousands) 2016 $ 775 2017 552 2018 584 2019 618 2020 65,853 Thereafter 12,053 $ 80,435

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	The Company’s net loss per share is as follows: Years Ended June 30, 2015 2014 2013 (In thousands, except share and per share data) Numerator Net loss $ (90,849 ) $ (57,899 ) $ (63,198 ) Denominator Weighted average number of shares used to compute basic net loss per share 112,194,900 98,062,664 81,165,773 Effect of dilutive options to purchase common stock — — — Weighted average number of shares used to compute diluted net loss per share 112,194,900 98,062,664 81,165,773 Basic and diluted net loss per share $ (0.81 ) $ (0.59 ) $ (0.78 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Components of Income (Loss) Before Income Taxes	For the years ended June 30, 2015, 2014 and 2013, income (loss) before income taxes consists of the following: Years Ended June 30, 2015 2014 2013 (In thousands) Domestic $ (89,617 ) $ (58,784 ) $ (63,752 ) International (1,232 ) 885 554 $ (90,849 ) $ (57,899 ) $ (63,198 )
Income Tax Expense (Benefit)	Income tax expense (benefit) is as follows: Years Ended June 30, 2015 2014 2013 Current Deferred Total Current Deferred Total Current Deferred Total (In thousands) U.S. Federal $ — $ (27,385 ) $ (27,385 ) $ — $ (18,415 ) $ (18,415 ) $ — $ (21,188 ) $ (21,188 ) State — (8,684 ) (8,684 ) — (5,839 ) (5,839 ) — (6,226 ) (6,226 ) International — (369 ) (369 ) — 266 266 — 177 177 Changes in valuation allowance — 36,438 36,438 — 23,988 23,988 — 27,237 27,237 Income tax provision $ — $ — $ — $ — $ — $ — $ — $ — $ —
U.S. Federal Income Tax Rate to Pretax Income (Loss)	Income tax expense (benefit) was $0 for the years ended June 30, 2015, 2014 and 2013 and differed from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) as a result of the following: Years Ended June 30, 2015 2014 2013 Tax at U.S. statutory rate (35 )% (35 )% (35 )% State taxes, net of federal benefit (6 )% (6 )% (10 )% Non-deductible and non-taxable items 1 % — 1 % Change in valuation allowance 40 % 41 % 44 % 0 % 0 % 0 %
Significant Components of Deferred Taxes	The tax effects of temporary differences and net operating losses that give rise to significant portions of deferred tax assets (liabilities) at June 30, 2015 and 2014 are presented below: June 30, 2015 2014 (In thousands) Net operating loss carryforwards $ 110,876 $ 89,362 Share-based compensation expense 20,548 16,532 Deferred revenue 6,951 — Depreciation differences 4,324 2,399 Accruals/Reserves 3,517 2,104 Valuation allowance (146,216 ) (110,397 ) Net deferred taxes $ — $ —

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Values of Company's Financial Instruments	The estimated fair values of the Company’s financial instruments are as follows: June 30, 2015 June 30, 2014 Carrying Estimated Carrying Estimated (In thousands) Amended Royalty Agreement liability $ 9,930 $ 9,930 $ 6,400 $ 6,400
Fair Value Measured on Recurring Basis	The following table presents the Company’s liabilities that are measured at fair value on a recurring basis for the periods presented: Fair Value Based On Quoted Market Significant Significant Total (In thousands) Amended Royalty Agreement liability: June 30, 2015 $ — $ — $ 9,930 $ 9,930 June 30, 2014 $ — $ — $ 6,400 $ 6,400
Schedule of Changes in Fair Value of Level 3 Financial Instruments	The following table presents the changes in the fair value of the level 3 financial instruments for the years ended June 30, 2015 and 2014. Royalty June 30, 2013 $ — Allocation of initial proceeds 7,000 Decrease in royalty liability (600 ) June 30, 2014 $ 6,400 Royalty payments (749 ) Increase in royalty liability 4,279 June 30, 2015 $ 9,930

Quarterly Results (unaudited) (

Quarterly Results (unaudited) (Tables)	12 Months Ended
	Jun. 30, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results	Quarter Ended Quarter Ended Quarter Ended Quarter Ended (In thousands, except per share data) Year Ended June 30, 2015 Revenues $ 1,380 $ 5,403 $ 2,921 $ 3,454 Gross profit 1,380 5,403 2,921 3,454 Net loss (22,262 ) (19,387 ) (23,105 ) (26,095 ) Basic and diluted loss per share $ (0.21 ) $ (0.18 ) $ (0.20 ) $ (0.22 ) Quarter Ended Quarter Ended Quarter Ended Quarter Ended (In thousands, except per share data) Year Ended June 30, 2014 Revenues $ 3,187 $ 3,573 $ 1,383 $ 6,546 Gross profit 3,187 3,573 1,383 6,546 Net loss (11,244 ) (16,283 ) (15,109 ) (15,263 ) Basic and diluted loss per share $ (0.12 ) $ (0.17 ) $ (0.15 ) $ (0.15 )

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($)	Sep. 14, 2015	Jul. 29, 2015	Jul. 31, 2015	Sep. 14, 2015	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Liquidity And Capital Resources [Line Items]
Issuance of common stock, value						$ 57,134,000	$ 16,856,000	$ 39,682,000
Common stock issued price, net of issuance costs						$ 57,134,000	$ 16,856,000	$ 42,707,000
Subsequent Event [Member]
Liquidity And Capital Resources [Line Items]
Percentage of reduction in workforce	17.00%
Reduction in operating cost due to workforce reduction	$ 4,300,000
Subsequent Event [Member] | New Sales Agreement with Cantor Fitzgerald & Co. [Member]
Liquidity And Capital Resources [Line Items]
Number of shares of common stock issued				2,870,689
Issuance of common stock, value				$ 3,800,000
Subsequent Event [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]
Liquidity And Capital Resources [Line Items]
Common stock issued price, net of issuance costs		$ 0	$ 4,800,000	$ 4,800,000
Common Stock [Member]
Liquidity And Capital Resources [Line Items]
Number of shares of common stock issued						18,458,800	5,012,153	15,605,400
Issuance of common stock, value						$ 185,000	$ 50,000	$ 156,000
Common Stock [Member] | Subsequent Event [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]
Liquidity And Capital Resources [Line Items]
Number of shares of common stock issued		451,354		3,244,650
Maximum [Member] | Subsequent Event [Member] | New Sales Agreement with Cantor Fitzgerald & Co. [Member]
Liquidity And Capital Resources [Line Items]
Aggregate offering price		$ 25,000,000
Maximum [Member] | Common Stock [Member] | Subsequent Event [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]
Liquidity And Capital Resources [Line Items]
Aggregate offering price		$ 45,000,000
Scenario, Forecast [Member] | Operating Expense [Member]
Liquidity And Capital Resources [Line Items]
Workforce reduction charges					$ 400,000

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Estimated Useful Life of Asset (Detail)	12 Months Ended
	Jun. 30, 2015
Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	2 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Computer Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Computer Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	Shorter of leasehold improvement life or remaining term of lease

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2015USD ($)Segment	Jun. 30, 2014USD ($)	Jun. 30, 2013USD ($)	Jun. 30, 2012USD ($)
Accounting Policies [Abstract]
Interest capitalized	$ 2,200,000	$ 0	$ 0
Company's market capitalization based on NASDAQ	283,700,000
Stockholders equity	$ (17,914,000)	6,131,000	35,598,000	$ 43,745,000
Estimated useful life of intangible assets	15 years
Income tax realized	50.00%
Gain (losses) from foreign currency transactions	$ 100,000	100,000	100,000
Total advertisement costs	$ 200,000	$ 200,000	$ 200,000
Number of reportable segment | Segment	1

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Sales by Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Revenue	$ 3,454	$ 2,921	$ 5,403	$ 1,380	$ 6,546	$ 1,383	$ 3,573	$ 3,187	$ 13,158	$ 14,689	$ 2,743
Domestic [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Revenue									9,834	5,702	120
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Revenue									$ 3,324	$ 8,987	$ 2,623

Equity Transactions and Share40

Equity Transactions and Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Nov. 14, 2014	Jun. 30, 2013	Apr. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2010	Mar. 31, 2013
Equity Transactions And Share Based Compensation [Line Items]
Common stock issued price, net of issuance costs				$ 57,134	$ 16,856	$ 42,707
Value of new stock issued				$ 57,134	16,856	$ 39,682
Number of warrants issued		2				2
Common shares underlying warrants						1,586,988
Exercise price of warrants		$ 3				$ 3
Expiration period of warrants						5 years
Liability of negotiated value of the warrants					$ 400			$ 3,000
Common stock shares issued			1,424,220
Number of warrants exercised			1
Issuance of common stock to directors						75,000
Shares not available for sale or transfer				175,000	227,500	45,000
Restricted stock value per share on grant date				$ 2.83	$ 3.95	$ 3.17
Share-based compensation expense				$ 11,800	$ 8,300	$ 13,300
Total compensation cost related to all non-vested awards not yet recognized				$ 26,800
Weighted average number of years for recognizing compensation expense				2 years 1 month 6 days
Maximum shares not considered for sale and transfer							6,000,000
Share reserve adjustment percentage							17.50%
Total intrinsic value				$ 100	1,800	$ 100
Expected dividend yield				0.00%
Underwritten Registered Offering [Member]
Equity Transactions And Share Based Compensation [Line Items]
Shares of common stock issued				12,650,000		6,154,000
Common stock issued price, net of issuance costs				$ 44,700		$ 18,800
Restricted Stock [Member]
Equity Transactions And Share Based Compensation [Line Items]
Restricted stock value per share on grant date				$ 2.83
Fair value of the options being expensed, service period				2 years 7 months 6 days
Shares of restricted stock issued	4,000,000
Consecutive trading period				30 days
Percentage of vested shares prior to first anniversary of the grant date				100.00%
Percentage of vested shares on or after third anniversary of the grant date				25.00%
Total fair value of shares vested during the period				$ 3,400	$ 6,000	$ 18,200
Restricted Stock [Member] | Chairman and Chief Executive Officer [Member]
Equity Transactions And Share Based Compensation [Line Items]
Restricted stock value per share on grant date	$ 1.885
Warrants [Member]
Equity Transactions And Share Based Compensation [Line Items]
Common shares underlying warrants		100,000
Common stock shares issued					19,471
Common Stock Warrants Liability [Member]
Equity Transactions And Share Based Compensation [Line Items]
Common shares underlying warrants			1,486,988
Reclassification of warrants related to equity			$ 2,800
Minimum [Member] | Restricted Stock [Member]
Equity Transactions And Share Based Compensation [Line Items]
Consecutive trading period				20 days
Trading price per share				$ 6
Maximum [Member] | Restricted Stock [Member]
Equity Transactions And Share Based Compensation [Line Items]
Trading price per share				$ 12
Old Sales Agreement [Member]
Equity Transactions And Share Based Compensation [Line Items]
Shares of common stock issued				5,808,800	5,012,153	4,990,434
Aggregate offering price of common stock up to which it can be issued and sold						$ 45,000
Common stock issued price, net of issuance costs					$ 16,900	$ 14,300
Value of new stock issued				$ 12,400
Securities Purchase Agreement [Member]
Equity Transactions And Share Based Compensation [Line Items]
Shares of common stock issued						4,460,966
Common stock issued price, net of issuance costs						$ 9,600
Employee Stock Option [Member] | Minimum [Member]
Equity Transactions And Share Based Compensation [Line Items]
Fair value of the options being expensed, service period				1 year
Employee Stock Option [Member] | Maximum [Member]
Equity Transactions And Share Based Compensation [Line Items]
Fair value of the options being expensed, service period				3 years
Amended Stock Plan [Member]
Equity Transactions And Share Based Compensation [Line Items]
Common stock available for issuance				10,000,000
Stock Incentive Plan [Member]
Equity Transactions And Share Based Compensation [Line Items]
Grant date fair value					$ 1.67	$ 1.69
Number of stock options granted				0

Equity Transactions and Share41

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Employees and Directors (Detail) - Employees and Directors [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2015
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Options and Warrants, Outstanding, Beginning	3,922,411
Number of Options, Cancelled	(170,257)
Number of Options, Expired	(1,234,000)
Number of Options, Exercised	(10,000)
Number of Options and Warrants, Outstanding, Ending	2,508,154
Number of Options, Exercisable, Ending	1,908,154
Weighted Average Exercise Price, Outstanding, Beginning	$ 4.67
Weighted Average Exercise Price, Cancelled	5.43
Weighted Average Exercise Price, Expired	6.38
Weighted Average Exercise Price, Exercised	2.33
Weighted Average Exercise Price, Outstanding, Ending	3.78
Weighted Average Exercise Price, Exercisable, Ending	$ 3.83
Weighted Average Remaining Contractual Life (In Years), Outstanding Balance	6 years 4 months 24 days
Weighted Average Remaining Contractual Life (In Years), Exercisable Balance	6 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding Balance	$ 0
Aggregate Intrinsic Value, Exercisable Balance	$ 0

Equity Transactions and Share42

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Other than Employees and Directors (Detail) - Jun. 30, 2015 - Other Than Employees and Directors Warrants [Member] - USD ($) $ / shares in Units, $ in Thousands	Total
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Options and Warrants, Outstanding, Beginning	2,050,000
Number of Options and Warrants, Expired	(1,000,000)
Number of Options and Warrants, Outstanding, Ending	1,050,000
Number of Options and Warrants, Exercisable, Ending	1,050,000
Weighted Average Exercise Price, Outstanding, Beginning	$ 4.52
Weighted Average Exercise Price, Expired	4.86
Weighted Average Exercise Price, Outstanding, Ending	4.20
Weighted Average Exercise Price, Exercisable, Ending	$ 4.20
Weighted Average Remaining Contractual Life (In Years), Outstanding Balance	1 year 3 months 18 days
Weighted Average Remaining Contractual Life (In Years), Exercisable Balance	1 year 3 months 18 days
Aggregate Intrinsic Value, Outstanding Balance	$ 23
Aggregate Intrinsic Value, Exercisable Balance	$ 23

Equity Transactions and Share43

Equity Transactions and Share-Based Compensation - Summary of Outstanding and Exercisable Stock Options Held by Employees and Directors (Detail) - Jun. 30, 2015 - Employees and Directors [Member] - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options, Outstanding as of June 30, 2015	2,508,154
Outstanding Options, Weighted Average Exercise Price	$ 3.78
Exercisable Options, Exercisable as of June 30, 2015	1,908,154
Outstanding Options, Weighted Average Remaining Contractual Life (In Years)	6 years 4 months 24 days
Exercisable Options, Weighted Average Exercise Price	$ 3.83
Exercisable Options, Weighted Average Remaining Contractual Life (In Years)	6 years 2 months 12 days
0.00 - 5.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options, Outstanding as of June 30, 2015	2,190,000
Outstanding Options, Weighted Average Exercise Price	$ 3.50
Exercisable Options, Exercisable as of June 30, 2015	1,590,000
Outstanding Options, Weighted Average Remaining Contractual Life (In Years)	6 years 9 months 18 days
Exercisable Options, Weighted Average Exercise Price	$ 3.46
Exercisable Options, Weighted Average Remaining Contractual Life (In Years)	6 years 7 months 6 days
5.01 - 7.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options, Outstanding as of June 30, 2015	318,154
Outstanding Options, Weighted Average Exercise Price	$ 5.69
Exercisable Options, Exercisable as of June 30, 2015	318,154
Outstanding Options, Weighted Average Remaining Contractual Life (In Years)	4 years 2 months 12 days
Exercisable Options, Weighted Average Exercise Price	$ 5.69
Exercisable Options, Weighted Average Remaining Contractual Life (In Years)	4 years 2 months 12 days

Equity Transactions and Share44

Equity Transactions and Share-Based Compensation - Summary of Outstanding and Exercisable Stock Options Held by Non-Employees and Non-Directors (Detail) - Jun. 30, 2015 - Persons Other Than Employees and Board Members [Member] - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options, Outstanding as of June 30, 2015	1,050,000
Exercisable Options, Exercisable as of June 30, 2015	1,050,000
Outstanding Options, Weighted Average Exercise Price	$ 4.20
Exercisable Options, Weighted Average Exercise Price	$ 4.20
Outstanding Options, Weighted Average Remaining Contractual Life (In Years)	1 year 3 months 18 days
Exercisable Options, Weighted Average Remaining Contractual Life (In Years)	1 year 3 months 18 days
0.00 - 2.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options, Outstanding as of June 30, 2015	150,000
Exercisable Options, Exercisable as of June 30, 2015	150,000
Outstanding Options, Weighted Average Exercise Price	$ 2
Exercisable Options, Weighted Average Exercise Price	$ 2
Outstanding Options, Weighted Average Remaining Contractual Life (In Years)	9 months 18 days
Exercisable Options, Weighted Average Remaining Contractual Life (In Years)	9 months 18 days
2.01 - 6.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options, Outstanding as of June 30, 2015	900,000
Exercisable Options, Exercisable as of June 30, 2015	900,000
Outstanding Options, Weighted Average Exercise Price	$ 4.57
Exercisable Options, Weighted Average Exercise Price	$ 4.57
Outstanding Options, Weighted Average Remaining Contractual Life (In Years)	1 year 4 months 24 days
Exercisable Options, Weighted Average Remaining Contractual Life (In Years)	1 year 4 months 24 days

Equity Transactions and Share45

Equity Transactions and Share-Based Compensation - Fair Value of Options and Warrants (Detail) - shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Stock Options and Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options granted		500,000	810,000
Expected dividend yield		0.00%	0.00%
Risk-free interest rate		1.52%	1.03%
Expected volatility		55.00%	55.00%
Expected life (in years)		5 years 6 months	5 years 5 months 9 days

Equity Transactions and Share46

Equity Transactions and Share-Based Compensation - Summary of Activity Related to Restricted Stock Awards (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value, Granted	$ 2.83	$ 3.95	$ 3.17
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested, Beginning balance	2,436,061
Number of Restricted Stock Awards, Granted	9,507,434
Number of Restricted Stock Awards, Vested	(947,344)
Number of Restricted Stock Awards, Cancelled	(264,375)
Number of Restricted Stock Awards, Unvested, Ending balance	10,731,776	2,436,061
Weighted Average Grant Date Fair Value, Unvested, Beginning Balance	$ 3.42
Weighted Average Grant Date Fair Value, Granted	2.83
Weighted Average Grant Date Fair Value, Vested	3.54
Weighted Average Grant Date Fair Value, Cancelled	3.42
Weighted Average Grant Date Fair Value, Unvested, Ending Balance	$ 2.89	$ 3.42

Property, Plant and Equipment -

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Abstract]
Building	$ 32,359	$ 32,188
Machinery and equipment	27,530	21,224
Computer software	2,910	2,675
Furniture and fixtures	1,345	610
Construction in progress	17,601	9,119
Land	2,036	2,036
Leasehold improvements	270	166
Property, plant and equipment, gross	84,051	68,018
Less: accumulated depreciation and amortization	(17,903)	(13,430)
Property, plant and equipment, net	$ 66,148	$ 54,588

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 11,830	$ 11,498
Foreign currency translation	(2,145)	332
Ending Balance	$ 9,685	$ 11,830

Accrued Expenses - Components o

Accrued Expenses - Components of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Payables and Accruals [Abstract]
Accrued payroll and other employee related expenses	$ 2,781	$ 2,103
Accrued other	2,293	1,236
Total accrued expenses	$ 5,074	$ 3,339

Commitments and Contingencies -

Commitments and Contingencies - Future Minimum Lease Payments Related to the Company's Non-cancellable Operating Lease Commitments (Detail) $ in Thousands	Jun. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 1,237
2,017	1,244
2,018	1,256
2,019	1,259
2,020	1,283
Thereafter	2,639
Total	$ 8,918

Commitments and Contingencies51

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Rental expenses under operating leases	$ 0.9	$ 0.6	$ 0.3

Long-Term Debt - Components of

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Debt Instrument [Line Items]
Long-term debt	$ 80,435	$ 55,448
Long-term debt	80,435	55,448
Less: current portion of long-term debt	775	613
Total long-term debt	79,660	54,835
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]
Debt Instrument [Line Items]
Long-term debt	2,033	2,087
Long-term debt	2,033	2,087
Other [Member]
Debt Instrument [Line Items]
Long-term debt	142	276
Long-term debt	142	276
10.25% Term Loan, Due March 2020 [Member]
Debt Instrument [Line Items]
Long-term debt	55,518	33,457
Long-term debt	55,518	33,457
Amended Royalty Agreement Liability [Member]
Debt Instrument [Line Items]
Long-term debt	9,930	6,400
Long-term debt	9,930	6,400
6.00% Mortgage Loans, Due December 2031 [Member]
Debt Instrument [Line Items]
Long-term debt	12,812	13,228
Long-term debt	$ 12,812	$ 13,228

Long-Term Debt - Components o53

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail) - Jun. 30, 2015	Total
10.25% Term Loan, Due March 2020 [Member]
Debt Instrument [Line Items]
Long-term debt, percentage	10.25%
Long-term debt, due date	Mar. 12, 2020
6.00% Mortgage Loans, Due December 2031 [Member]
Debt Instrument [Line Items]
Long-term debt, percentage	6.00%
Long-term debt, due date	Dec. 31, 2031
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]
Debt Instrument [Line Items]
Long-term debt, percentage	5.00%
Long-term debt, due date	Jan. 31, 2021

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail)

Jun. 15, 2015USD ($)

Dec. 15, 2014USD ($)

Nov. 10, 2014USD ($)

Oct. 01, 2014USD ($)

Sep. 30, 2014Tranches

Mar. 12, 2014USD ($)Tranches

Sep. 30, 2013

Oct. 31, 2010USD ($)Note

Aug. 31, 2011USD ($)

Dec. 31, 2010USD ($)

Dec. 31, 2014USD ($)

Jun. 30, 2015USD ($)Unit

Jun. 30, 2014USD ($)

Jun. 30, 2013USD ($)

Debt Instrument [Line Items]

Committed principal amount of term loan

$ 60,000,000

Proceeds from tranche loan

$ 10,000,000

$ 40,000,000

$ 20,000,000

$ 40,000,000

Number of additional tranches | Tranches

2

Repayment premium on unpaid principle amount of loans

10.00%

Percentage of repayment of debt from proceeds on sale of assets and casualty events

100.00%

Minimum liquidity amount

$ 5,000,000

Loans determined, fair value

$ 33,000,000

Number of separate units reported | Unit

2

Mortgage loans, amount

$ 80,435,000

55,448,000

Lease buyout rate

15.00%

Lease period

2 years

Additional lease period

1 year

Lease payment

4,800,000

Interest expense

$ 6,368,000

7,332,000

$ 2,392,000

Definitive Settlement Agreement [Member]

Debt Instrument [Line Items]

Interest expense

3,600,000

Debt Instrument, Periodic Payment

4,700,000

Commonwealth of Pennsylvania Financing Authority Loan [Member]

Debt Instrument [Line Items]

Interest rate per annum

5.00%

Long-term debt, due date

Jan. 31, 2021

Loan amount for financing for land and construction of current manufacturing facility

$ 2,250,000

Amended Credit Agreement [Member]

Debt Instrument [Line Items]

Proceeds from tranche loan

$ 20,000,000

Number of additional tranches | Tranches

2

First Tranche [Member] | Amended Credit Agreement [Member]

Debt Instrument [Line Items]

Proceeds from tranche loan

$ 10,000,000

Second Tranche [Member] | Amended Credit Agreement [Member]

Debt Instrument [Line Items]

Proceeds from tranche loan

$ 10,000,000

Secured Lending Facility [Member]

Debt Instrument [Line Items]

Master Lease Agreement with Varilease Finance, Inc. for secured financing

$ 10,000,000

Effective interest rate

14.00%

Frequency of payment as per agreement

27 monthly installments based upon the amount drawn

Metro Banks [Member]

Debt Instrument [Line Items]

Debt service reserve account

$ 2,400,000

Required to maintain a cash balance under financial covenants

5,000,000

Minimum balance in Debt service reserve account

$ 1,600,000

June 15, 2015 [Member]

Debt Instrument [Line Items]

Proceeds from tranche loan

$ 10,000,000

Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Agreement buyout date

Mar. 12, 2018

Amended Royalty Agreement [Member] | 3.875% [Member]

Debt Instrument [Line Items]

Royalty percentage on first $50 million of net sales

3.875%

Amended Royalty Agreement [Member] | 3.875% Plus 1.500% [Member]

Debt Instrument [Line Items]

Royalty percentage on second $50 million of net sales

1.50%

Amended Royalty Agreement [Member] | 3.875% Plus 1.500% Plus 0.375% [Member]

Debt Instrument [Line Items]

Royalty percentage on net sales in excess of $100 million

0.375%

Amended Royalty Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Buy out amount

$ 26,250,000

Amended Royalty Agreement [Member] | Maximum [Member] | 3.875% [Member]

Debt Instrument [Line Items]

Net sales

50,000,000

Amended Royalty Agreement [Member] | Maximum [Member] | 3.875% Plus 1.500% [Member]

Debt Instrument [Line Items]

Net sales

100,000,000

Amended Royalty Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Buy out amount

9,750,000

Amended Royalty Agreement [Member] | Minimum [Member] | 3.875% Plus 1.500% [Member]

Debt Instrument [Line Items]

Net sales

50,000,000

Amended Royalty Agreement [Member] | Minimum [Member] | 3.875% Plus 1.500% Plus 0.375% [Member]

Debt Instrument [Line Items]

Net sales

$ 100,000,000

10.25% Term Loan, Due March 2020 [Member]

Debt Instrument [Line Items]

Interest rate per annum

9.25%

Additional interest rate on LIBOR

1.00%

Term loan, interest rate terms

The Loan bears interest at 9.25% per annum plus the greater of three-month LIBOR or 1.0%

Term loan, default interest rate, fixed percentage

14.25%

Term loan, default interest rate, variable percentage

1.00%

Term loan ,default interest rate terms

A default interest rate of 14.25% per annum plus the greater of three-month LIBOR or 1.0%

Long-term debt, due date

Mar. 12, 2020

Mortgage loans, amount

$ 55,518,000

33,457,000

Mortgage Loans [Member] | Metro Banks [Member]

Debt Instrument [Line Items]

Number of mortgage loans | Note

2

Mortgage Loan 1 [Member] | Metro Banks [Member]

Debt Instrument [Line Items]

Interest rate per annum

6.00%

Mortgage loans, amount

$ 14,250,000

Mortgage Loan 2 [Member] | Metro Banks [Member]

Debt Instrument [Line Items]

Mortgage loans, amount

$ 3,750,000

6.00% Mortgage Loans, Due October 2020 [Member] | Metro Banks [Member]

Debt Instrument [Line Items]

Long-term debt, due date

Oct. 31, 2020

6.00% Mortgage Loans, Due December 2031 [Member]

Debt Instrument [Line Items]

Long-term debt, due date

Dec. 31, 2031

Mortgage loans, amount

$ 12,812,000

13,228,000

6.00% Mortgage Loans, Due December 2031 [Member] | Metro Banks [Member]

Debt Instrument [Line Items]

Long-term debt, due date

Dec. 31, 2031

Amount of loans guaranteed by U.S. Department of Agriculture

$ 8,000,000

March 12, 2014 Credit Agreement [Member] | Definitive Settlement Agreement [Member]

Debt Instrument [Line Items]

Proceeds from credit agreement

3,500,000

Amended Royalty Agreement Liability [Member]

Debt Instrument [Line Items]

Royalty Agreement liability

$ 7,000,000

9,900,000

Mortgage loans, amount

$ 9,930,000

$ 6,400,000

Long-Term Debt - Aggregate Matu

Long-Term Debt - Aggregate Maturities of Long-term Obligations (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Debt Disclosure [Abstract]
2,016	$ 775
2,017	552
2,018	584
2,019	618
2,020	65,853
Thereafter	12,053
Long-term debt	$ 80,435	$ 55,448

Net Loss Per Share - Net Loss P

Net Loss Per Share - Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Numerator
Net loss	$ (26,095)	$ (23,105)	$ (19,387)	$ (22,262)	$ (15,263)	$ (15,109)	$ (16,283)	$ (11,244)	$ (90,849)	$ (57,899)	$ (63,198)
Denominator
Weighted average number of shares used to compute basic net loss per share									112,194,900	98,062,664	81,165,773
Effect of dilutive options to purchase common stock									0	0	0
Weighted average number of shares used to compute diluted net loss per share									112,194,900	98,062,664	81,165,773
Basic and diluted net loss per share	$ (0.22)	$ (0.20)	$ (0.18)	$ (0.21)	$ (0.15)	$ (0.15)	$ (0.17)	$ (0.12)	$ (0.81)	$ (0.59)	$ (0.78)

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Incremental shares in case of profit for calculating diluted earnings per share	0	0	0
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share excluded from calculation of basic and diluted net loss per share	6,990,214	2,687,775	4,909,091
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share excluded from calculation of basic and diluted net loss per share	3,500,596	4,642,725	7,996,935
Incremental shares in case of profit for calculating diluted earnings per share	145,735	323,854	595,550

Income Taxes - Components of In

Income Taxes - Components of Income (Loss) Before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Domestic									$ (89,617)	$ (58,784)	$ (63,752)
International									(1,232)	885	554
Net loss	$ (26,095)	$ (23,105)	$ (19,387)	$ (22,262)	$ (15,263)	$ (15,109)	$ (16,283)	$ (11,244)	$ (90,849)	$ (57,899)	$ (63,198)

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
U.S. Federal, Current	$ 0	$ 0	$ 0
State, Current	0	0	0
International, Current	0	0	0
Changes in valuation allowance, Current	0	0	0
Income tax provision, Current	0	0	0
U.S. Federal, Deferred	(27,385)	(18,415)	(21,188)
State, Deferred	(8,684)	(5,839)	(6,226)
International, Deferred	(369)	266	177
Changes in valuation allowance, Deferred	36,438	23,988	27,237
Income tax provision, Deferred	0	0	0
U.S. Federal, Total	(27,385)	(18,415)	(21,188)
State, Total	(8,684)	(5,839)	(6,226)
International, Total	(369)	266	177
Changes in valuation allowance, Total	36,438	23,988	27,237
Income tax provision, Total	$ 0	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 0	$ 0	$ 0
Valuation allowance	146,216,000	110,397,000
Change in total valuation allowance	35,800,000
Net operating loss carryforwards, U.S Federal	256,400,000
Net operating loss carryforwards, State	256,400,000
Net operating loss carryforwards, Australian	$ 22,700,000
Change in ownership as per federal and state net operating loss carryforwards	50.00%
Percentage of taxable income after modifications and apportionment	20.00%
State net operating losses utilized	$ 5,000,000
Unrecognized tax benefits	$ 0	$ 0	$ 0

Income Taxes - U.S. Federal Inc

Income Taxes - U.S. Federal Income Tax Rate to Pretax Income (Loss) (Detail)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Tax at U.S. statutory rate	(35.00%)	(35.00%)	(35.00%)
State taxes, net of federal benefit	(6.00%)	(6.00%)	(10.00%)
Non-deductible and non-taxable items	1.00%		1.00%
Change in valuation allowance	40.00%	41.00%	44.00%
Total	0.00%	0.00%	0.00%

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Taxes (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 110,876	$ 89,362
Share-based compensation expense	20,548	16,532
Deferred revenue	6,951
Depreciation differences	4,324	2,399
Accruals/Reserves	3,517	2,104
Valuation allowance	(146,216)	(110,397)
Net deferred taxes	$ 0	$ 0

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Compensation and Retirement Disclosure [Abstract]
Defined contribution plan maximum annual contribution percent per employee		100.00%
Defined contribution plan maximum annual earnings contribution per employer percent	3.00%
Defined contribution plan employers contribution annual vesting percentage year two	50.00%
Defined contribution plan employers contribution annual vesting percentage year three	100.00%
Employee contributions matched by company		$ 500,000	$ 300,000	$ 300,000
Discretionary contribution of compensation, Percentage		1.00%		1.00%
Discretionary contribution made by company		$ 100,000	$ 0	$ 100,000

Revenue - Additional Informatio

Revenue - Additional Information (Detail)	3 Months Ended								12 Months Ended
	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Sep. 30, 2013USD ($)	Jun. 30, 2015USD ($)Customer	Jun. 30, 2014USD ($)CustomerProduct	Jun. 30, 2013USD ($)Customer
Concentration Risk [Line Items]
Revenue	$ 3,454,000	$ 2,921,000	$ 5,403,000	$ 1,380,000	$ 6,546,000	$ 1,383,000	$ 3,573,000	$ 3,187,000	$ 13,158,000	$ 14,689,000	$ 2,743,000
Revenue recognized related to substantive milestones									$ 5,100,000	$ 8,100,000
Consolidated Revenue [Member]
Concentration Risk [Line Items]
Number of customers accounted for consolidated revenue | Customer									3	3	1
Sales Revenue, Net [Member] | Consolidated Revenue [Member] | France [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage									24.00%	15.00%	96.00%
Sales Revenue, Net [Member] | Consolidated Revenue [Member] | Jordan [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage										34.00%
Customer One [Member] | Sales Revenue, Net [Member] | Consolidated Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage									35.00%	34.00%	96.00%
Customer Two [Member] | Sales Revenue, Net [Member] | Consolidated Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage									32.00%	23.00%
Customer Three [Member] | Sales Revenue, Net [Member] | Consolidated Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage									24.00%	15.00%
Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									$ 2,700,000
Initial up-front payment									100,000
Feasibility Agreement One [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									900,000
Initial up-front payment									500,000
Feasibility Agreement One [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									300,000
Remaining substantive milestones revenue									0
Feasibility Agreement One [Member] | Milestone Five [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									200,000
Remaining substantive milestones revenue									0
Clinical Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										$ 1,300,000
Remaining substantive milestones revenue										0
Customization and Commercial Supply Agreement [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										800,000
Materials Transfer Agreement [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										700,000
Remaining substantive milestones revenue										0
Collaborative Research Agreement [Member] | Milestone Four [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										300,000
Remaining substantive milestones revenue										0
Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									1,000,000
Initial up-front payment									1,100,000
Binding License, Development and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										5,000,000
Development and Delivery of Detailed Project Plan and Failure Mode and Effects Analysis Report [Member] | Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									400,000
Development and Delivery of Report on Preliminary Product Requirements and Risk Management Plan [Member] | Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									400,000
Development and Delivery of Human Factor Stimuli and Related Supporting Documents [Member] | Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									1,500,000
Development and Delivery of Additional Human Factor Stimuli [Member] | Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									400,000
Development and Delivery of Additional Human Factor Stimuli and Report on Updated Product Requirements [Member] | Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									500,000
Development and Delivery of Semi-functional Prototypes And Related Feasibility Product Requirement and Risk Management Reports [Member] | Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									1,200,000
Development and Delivery of Report on Device Design Options as Well as Potential Manufacturing and Assembly Processes [Member] | Feasibility Agreement One [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									500,000
Development and Delivery of Product Samples and Related Supporting Documents [Member] | Feasibility Agreement One [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									400,000
Development and Delivery of Summary Report Related to Testing and Documentation Activities [Member] | Feasibility Agreement One [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									200,000
Development and Delivery of Report Related to Human Factor Studies and Quality Requirements [Member] | Feasibility Agreement One [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									100,000
Development and Delivery of Devices for Compatibility and Stability Functional Testing and Related Reporting [Member] | Feasibility Agreement One [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									100,000
Development and Delivery of Devices for Human Factor Study and Related Reporting [Member] | Feasibility Agreement One [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									100,000
Development Of Customized Devices For Testing [Member] | Feasibility Agreement One [Member] | Milestone Five [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									100,000
Development And Delivery Of Testing Activities And Related Reporting [Member] | Feasibility Agreement One [Member] | Milestone Five [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									100,000
Development and Delivery of Devices to be Used by Customer for Compatibility Testing [Member] | Clinical Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										400,000
Delivery of Development and Testing Activities [Member] | Clinical Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										100,000
Delivery of Development Testing and Verification Activities [Member] | Clinical Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										600,000
Development and Delivery of Testing Materials [Member] | Clinical Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										100,000
Certain Support and Testing Activities [Member] | Clinical Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										100,000
Customization and Delivery of Devices for Compatibility and Initial Evaluation Testing [Member] | Customization and Commercial Supply Agreement [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										800,000
Delivery of Devices for Clinical Studies [Member] | Customization and Commercial Supply Agreement [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue										800,000
Delivery of Devices for Clinical Studies [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									300,000
Certain Delivery of Services Supporting Customers Regulatory Approval Process [Member] | Customization and Commercial Supply Agreement [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue										200,000
Delivery of Testing Materials [Member] | Materials Transfer Agreement [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										400,000
Delivery of Device Design Requirements [Member] | Materials Transfer Agreement [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										100,000
Delivery of Customization Activities [Member] | Materials Transfer Agreement [Member] | Milestone Three [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										200,000
Customization and Delivery of Devices for Evaluation and User Study Purposes [Member] | Collaborative Research Agreement [Member] | Milestone Four [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										100,000
Customization and Delivery of Devices for Evaluation Activities [Member] | Collaborative Research Agreement [Member] | Milestone Four [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones										200,000
Development and Delivery of Report Defining Device Requirements [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									200,000
Development and Delivery of Report Defining System Requirements [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									200,000
Development and Delivery of Devices for Testing [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									200,000
Development and Delivery of Report Defining Production Requirements [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									200,000
Development and Delivery of Components for Human Factor Study [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones									200,000
Remaining substantive milestones revenue									300,000
Development and Delivery of Complete System Layout [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									600,000
Development and Delivery of Feasibility Devices for Testing [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									600,000
Development and Delivery of Clinical Production Process [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									600,000
Development and Delivery of Components for Human Factor Study One [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									400,000
Completion of Testing of Assembly Equipment [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									400,000
Completion of Filling Process of Clinical Devices [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									300,000
Delivery of Containers for Filling Process [Member] | Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue									400,000
Customization, Design and Production of Prototype Device for Incorporation Into Drug Delivery System [Member] | Binding License, Development and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue										5,000,000
Delivery and Acceptance of Application for Regulatory Approval [Member] | Binding License, Development and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue										$ 1,000,000
Regulatory Approval for up to 20 Drug-Delivery Device Combination Products [Member] | Binding License, Development and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Number of drug-delivery device combination products | Product										20
Other Sales [Member]
Concentration Risk [Line Items]
Revenue											$ 100,000
Customer Agreements [Member]
Concentration Risk [Line Items]
Revenue									$ 8,100,000	$ 4,300,000
License Agreements [Member] | Sanofi [Member]
Concentration Risk [Line Items]
Revenue										$ 2,300,000	$ 2,600,000

Financial Instruments - Fair Va

Financial Instruments - Fair Values of Company's Financial Instruments (Detail) - Amended Royalty Agreement Liability [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total Fair Value Measurements	$ 9,930	$ 6,400
Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total Fair Value Measurements	9,930	6,400
Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total Fair Value Measurements	$ 9,930	$ 6,400

Financial Instruments - Fair 66

Financial Instruments - Fair Value Measured on Recurring Basis (Detail) - Amended Royalty Agreement Liability [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Fair Value Measurements	$ 9,930	$ 6,400
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Fair Value Measurements	$ 9,930	$ 6,400

Financial Instruments - Schedul

Financial Instruments - Schedule of Changes in Fair Value of Level 3 Financial Instruments (Detail) - Royalty Agreement Liability [Member] - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 6,400
Royalty payments	(749)
Allocation of initial proceeds		$ 7,000
Increase (decrease) in royalty liability	4,279	(600)
Ending balance	$ 9,930	$ 6,400

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Related Party Transactions [Abstract]
Related party transaction consultancy expenses paid	$ 0.2	$ 0.2	$ 0.2

Quarterly Results (Unaudited) -

Quarterly Results (Unaudited) - Quarterly Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 3,454	$ 2,921	$ 5,403	$ 1,380	$ 6,546	$ 1,383	$ 3,573	$ 3,187	$ 13,158	$ 14,689	$ 2,743
Gross profit	3,454	2,921	5,403	1,380	6,546	1,383	3,573	3,187
Net loss	$ (26,095)	$ (23,105)	$ (19,387)	$ (22,262)	$ (15,263)	$ (15,109)	$ (16,283)	$ (11,244)	$ (90,849)	$ (57,899)	$ (63,198)
Basic and diluted loss per share	$ (0.22)	$ (0.20)	$ (0.18)	$ (0.21)	$ (0.15)	$ (0.15)	$ (0.17)	$ (0.12)	$ (0.81)	$ (0.59)	$ (0.78)

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Sep. 14, 2015Employee	Jul. 29, 2015USD ($)shares	Jul. 31, 2015USD ($)	Sep. 14, 2015USD ($)Employeeshares	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)shares	Jun. 30, 2013USD ($)shares
Subsequent Event [Line Items]
Issuance of common stock, value						$ 57,134,000	$ 16,856,000	$ 39,682,000
Proceeds from the issuance of common stock, net of issuance costs						$ 57,134,000	$ 16,856,000	$ 42,707,000
Scenario, Forecast [Member] | Operating Expense [Member]
Subsequent Event [Line Items]
Workforce reduction charges					$ 400,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Reduction in workforce, headcount | Employee	50			50
Percentage of reduction in workforce	17.00%
Subsequent Event [Member] | New Sales Agreement with Cantor Fitzgerald & Co. [Member]
Subsequent Event [Line Items]
Number of shares of common stock issued | shares				2,870,689
Issuance of common stock, value				$ 3,800,000
Subsequent Event [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Proceeds from the issuance of common stock, net of issuance costs		$ 0	$ 4,800,000	$ 4,800,000
Purchase agreement term		24 months
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares of common stock issued | shares						18,458,800	5,012,153	15,605,400
Issuance of common stock, value						$ 185,000	$ 50,000	$ 156,000
Common Stock [Member] | Subsequent Event [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Number of shares of common stock issued | shares		451,354		3,244,650
Common stock purchases amount			$ 5,000,000
Maximum [Member] | Subsequent Event [Member] | New Sales Agreement with Cantor Fitzgerald & Co. [Member]
Subsequent Event [Line Items]
Aggregate offering price		$ 25,000,000
Commission percentage of gross sales price per share		3.00%
Maximum [Member] | Subsequent Event [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Additional common stock shares issued		$ 40,000,000
Purchase of common stock shares | shares		200,000
Proceeds from purchase of common stock		$ 2,000,000
Maximum [Member] | Common Stock [Member] | Subsequent Event [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Aggregate offering price		$ 45,000,000